Previous Article | Next Article 
Clinical Microbiology Reviews, October 2008, p. 639-665, Vol. 21, No. 4
0893-8512/08/$08.00+0 doi:10.1128/CMR.00022-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
New Insights on Classification, Identification, and Clinical Relevance of Blastocystis spp.
Kevin S. W. Tan*
Laboratory of Molecular and Cellular Parasitology, Department of Microbiology, Yong Loo Lin School of Medicine, 5 Science Drive 2, Singapore 117597, Republic of Singapore

SUMMARY
Summary:
Blastocystis is an unusual enteric protozoan parasite
of humans and many animals. It has a worldwide distribution
and is often the most commonly isolated organism in parasitological
surveys. The parasite has been described since the early 1900s,
but only in the last decade or so have there been significant
advances in our understanding of
Blastocystis biology. However,
the pleomorphic nature of the parasite and the lack of standardization
in techniques have led to confusion and, in some cases, misinterpretation
of data. This has hindered laboratory diagnosis and efforts
to understand its mode of reproduction, life cycle, prevalence,
and pathogenesis. Accumulating epidemiological, in vivo, and
in vitro data strongly suggest that
Blastocystis is a pathogen.
Many genotypes exist in nature, and recent observations indicate
that humans are, in reality, hosts to numerous zoonotic genotypes.
Such genetic diversity has led to a suggestion that previously
conflicting observations on the pathogenesis of
Blastocystis are due to pathogenic and nonpathogenic genotypes. Recent epidemiological,
animal infection, and in vitro host-
Blastocystis interaction
studies suggest that this may indeed be the case. This review
focuses on such recent advances and also provides updates on
laboratory and clinical aspects of
Blastocystis spp.

INTRODUCTION
Blastocystis is an unusual enteric protozoan parasite of humans
and many animals (
233,
250). It has a worldwide distribution
and is often the most commonly isolated organism in parasitological
surveys (
6,
8,
21,
25,
179,
198). The parasite has been described
since the early 1900s (
12,
37), but only in the last decade
or so have there been significant advances in our understanding
of
Blastocystis biology. However, the pleomorphic nature of
the parasite and the lack of standardization in techniques have
led to confusion and, in some cases, misinterpretation of data.
This has hindered laboratory diagnosis and efforts to understand
its mode of reproduction, life cycle, prevalence, and pathogenesis.
Accumulating epidemiological, in vivo, and in vitro data strongly
suggest that
Blastocystis is a pathogen. Many genotypes exist
in nature, and recent observations indicate that humans are
in reality host to numerous zoonotic genotypes (
1,
169). Such
genetic diversity has led to a suggestion that previously conflicting
observations on its pathogenesis are due to pathogenic and nonpathogenic
genotypes (
53). Recent epidemiological, animal infection, and
in vitro host-
Blastocystis interaction studies suggest that
this may indeed be the case. This review will focus on such
recent advances and also provide updates on laboratory and clinical
aspects of
Blastocystis spp. Excellent reviews on various topics
in
Blastocystis biology, including historical perspectives on
parasite biology, animal isolates, and pathogenesis, were reported
elsewhere previously (
33,
233,
250,
256,
319).

CLASSIFICATION
Genetic Diversity
Blastocystis spp. from humans and animals have been reported
to be morphologically similar. This is probably an oversimplification,
as there have been reports describing distinct morphological
differences among
Blastocystis isolates (
219,
236,
237,
303).
However, it is nevertheless challenging to differentiate one
isolate from another based on morphological criteria alone.
Interestingly, extensive genetic variation has been observed
among numerous isolates from both humans and animals. A number
of molecular techniques to study the genetic diversity of
Blastocystis spp. have been described. The techniques commonly employed are
PCR-restriction fragment length polymorphism (RFLP) (
2-
4,
31,
53,
113,
202,
223,
271,
305), PCR followed by dideoxy sequencing
(
1,
17,
100,
169,
170,
214,
218,
231,
271,
304), and PCR with
subtype-specific (sequence-tagged site [STS]) primers (
2-
4,
117,
119-
121,
124,
128,
129). A few studies employed the use
of arbitrary primed PCR (
103,
125) or karyotyping (
38,
99,
219,
276). Clark (
52,
53), by PCR-RFLP of the entire small-subunit
rRNA (ssrRNA) gene, revealed a remarkable amount of genetic
variation that existed among 30 randomly selected human isolates.
These RFLP profiles (riboprints) could be grouped into seven
distinct genotypes (ribodemes). It was previously observed that
there was a 7% divergence between ribodemes 1 and 2, which is
approximately four times the genetic distance between homologous
genes of
Entamoeba histolytica and
Entamoeba dispar (
53). In
the most extensive phylogenetic study to date, Noël et
al. (
169) analyzed the ssrRNA genes of 12
Blastocystis isolates
from humans, rats, and reptiles together with 78 other
Blastocystis sequences available in the GenBank database at the time of the
study. They showed that
Blastocystis spp. could be unambiguously
placed within seven distinct clades, with six of the major groups
comprising isolates from both humans and animals. Those authors
concluded that numerous zoonotic isolates existed, with frequent
animal-to-human and human-to-animal transmissions, and that
animals represent a large potential reservoir for human infections.
Thus, in the absence of genotype information and due to the
extreme genetic diversity among
Blastocystis isolates, caution
is warranted when interpreting data or when extrapolating observations
of morphology, drug sensitivity, and pathogenesis from one isolate
to another.
Phylogenetic Studies and Identification of Isolates to the Species Level
The taxonomic classification of
Blastocystis spp. has proven
challenging and was only recently unambiguously placed within
the stramenopiles despite the application of modern molecular
phylogenetic approaches (
18,
100,
218). The organism was initially
classified as the cyst of a flagellate, vegetable, yeast, and
fungus (
319). It was subsequently reclassified as a protist
by Zierdt and colleagues (
319,
322) based on a number of protistan
features, viz., one or more nuclei, smooth and rough endoplasmic
reticulum, Golgi bodies, and mitochondrion-like organelles;
it failed to grow on fungal media and was resistant to antifungal
drugs but was sensitive to the antiprotozoal drugs metronidazole
(Flagyl) and emetine (
319,
322). The subsequent molecular analysis
of
Blastocystis ssrRNA and elongation factor 1

(EF-1

) gene sequences
resulted in disparate conclusions on its taxonomic and phylogenetic
affiliations. An earlier analysis of the ssRNA genes showed
that
Blastocystis sp. is not monophyletic with the yeasts, fungi,
sarcodines, or sporozoans (
108) and should be placed among the
stramenopiles (
100,
218). In contrast, studies involving EF-1
suggested that
Blastocystis spp. diverged before the stramenopiles
and may be a close relative of
Entamoeba spp. (
97,
158). This
apparent discrepancy may be explained statistically by the low
bootstrap value (58.1) used to group
Blastocystis spp. with
E. histolytica. Other possibilities for the variation in affinities
exist. They may be due to the choice of genes for analysis.
The ssrRNA genes have been known to possess drastic G+C content
variation among species (
93), which may give rise to misleading
trees, and hence, other genes (e.g., EF-1

, EF-2, and RNA polymerase
III large subunit) with less extreme biases have been suggested
to be better candidates for phylogenetic studies. Other possible
factors contributing to the discrepancy include inadequate species
sampling, relatively few informative positions, mutational saturation,
and long-branch attraction phenomena (
186,
203,
204). A later
study involving sequences from multiple conserved genes sought
to resolve this discrepancy (
18). The molecular analysis of
Blastocystis ssrRNA, cytosolic-type 70-kDa heat shock protein,
translation elongation factor 2, and the noncatalytic "B" subunit
of vacuolar ATPase clearly demonstrated that
Blastocystis is
a stramenopile. The stramenopiles, synonymous with
Heterokonta and
Chromista (
42), are a complex collection of "botanical"
protists comprising heterotrophic and photosynthetic representatives.
Molecular phylogenetic studies indicated that
Blastocystis sp.
is most closely related to
Proteromonas lacertae (
18,
100,
218),
a flagellate of the hindgut of lizards and amphibians. Members
of the stramenopile group are characterized by possessing flagella
with mastigonemes (hair-like projections that extend laterally
from the flagellum). Interestingly,
Blastocystis sp. does not
possess flagella, is nonmotile, and is therefore placed in a
newly created class, class
Blastocystea, subphylum
Opalinata,
infrakingdom
Heterokonta, subkingdom
Chromobiota, kingdom
Chromista (
41). A recent phylogenetic study showed that, based on the
genetic distance between homologous genes,
Blastocystis spp.
from humans and animals can be potentially divided into 12 or
more species (
169). This and other studies have confirmed that
Blastocystis genotypes are prevalent throughout the animal kingdom,
with a number of genotypes comprising isolates from both humans
and animals (
1,
3,
4,
169,
214,
271,
295,
300,
305). In this
regard, the practice of assigning
Blastocystis species according
to host origin poses a problem and has probably resulted in
confusing reports regarding variations in pathogenesis and cell
biology, since these differences could be attributed to distinct
genotypes. Table
1 illustrates new designations for some well-studied
human and animal isolates based on a recently published consensus
terminology for
Blastocystis sp. (
229). Humans can be host to
Blastocystis spp. from various mammals (subtype 1), primates
and pigs (subtype 2), rodents (subtype 4), cattle and pigs (subtype
5), and birds (subtypes 6 and 7) (
169,
295). Subtype 3 is the
most frequently isolated genotype in epidemiological surveys
and is probably the only genotype of human origin (
31,
113,
291,
304). By phylogenetic analysis, subtypes 8 and 9 cluster
most closely to subtypes 4 and 6, respectively (
169,
214). We
have very little information on both these subtypes except that
subtype 8 has been reported in three studies (
1,
214,
228),
from monkeys, a pheasant, and humans, while subtype 9 was observed
in 2 human isolates out of 102 isolates in an epidemiological
study (
304). These distributions of specific genotypes among
various animal hosts should be viewed as tentative and would,
in due course, become more representative as additional studies
are performed. For example, subtype 5 is currently accepted
as being the main
Blastocystis genotype in pigs due the its
high prevalence in this host (
1,
295,
297). However, other studies
(
163,
271) showed that subtype 1 may dominates in pigs. Two
recent reports (
163,
201) revealed that pigs may harbor subtype
2, which, until those studies, comprised isolates only from
humans and primates.
Blastocystis cells often possess one or two nuclei, and occasionally,
quadrinucleate cells and cells possessing numerous nuclei have
been reported (
65,
142,
146,
319,
321). Whether these multinuclear
states impact molecular and phylogenetic analyses is currently
not known. Karyogamy and the exchange of genetic material have
recently been demonstrated in the binucleate enteric protozoan
parasite
Giardia intestinalis (
189). It is unknown if
Blastocystis also undergoes such a process, and if so, the implications of
such a phenomenon for the construction of phylogenetic trees
should be ascertained. Future studies should aim to elucidate
the ploidy of the
Blastocystis genome and to understand if it
is an asexual or sexual parasite, since such characteristics,
which affect the extent to which genes evolve, can have major
implications for how molecular phylogenetic data are interpreted
(
29,
174).

BIOLOGY
Morphological Forms
Blastocystis is a polymorphic protozoan, and four major forms
have been described in the literature (Fig.
1 to
5). In reality,
Blastocystis spp. can present with a bewildering array of forms
within a single culture, and it may be difficult to assign a
specific form to the cell in question (Fig.
1A and C). The extensive
variation in
Blastocystis forms has made studies of its cell
biology challenging, resulting in misinterpretations of data
from time to time. The central vacuole form, sometimes referred
to as the central body form, is the most frequently observed
form in laboratory culture and in stool samples. It is spherical
and may display large size variations, ranging from 2 to 200
µm (average of 4 to 15 µm) (
233). Extensive size
variation can occur within and between isolates (
65,
197). Dunn
et al. (
65) observed size variations of 4 to 63 µm among
10 human isolates; the mean diameters between stocks also varied
significantly, with overlap between some isolates. A study of
Blastocystis strains isolated from chickens revealed vacuolar
forms ranging from 3 to 120 µm in diameter (
132). The
vacuolar form is characterized by a large central vacuole that
occupies approximately 90% of the cell's volume (
142,
233) (Fig.
1A,
2A, and
5C to E). This relegates the cytoplasm and organelles
into a thin peripheral rim, which may sometimes be difficult
to visualize under light microscopy (Fig.
5A and C). Nuclei
and mitochondrion-like organelles are usually located within
thickened cytoplasmic regions at opposite ends of the cell (Fig.
5E). Certain amphibian isolates possess thick cytoplasmic rims,
which are easily discernible by conventional light microscopy
(
219). The central vacuole may appear empty or may contain fine
to flocculant material. It was reported to contain carbohydrates,
evidenced by positive staining with periodic acid-Schiff and
Alcian blue staining (
299), or lipids, evidenced by Sudan black
B and Nile blue staining (
302), suggesting a storage role for
the organelle. The vacuole has also been suggested to play a
role in schizogony-like reproduction (
220,
241) by providing
an environment for the development of minute parasite progeny.
This is highly unlikely considering that these progeny appear
strikingly similar to metabolic granules described previously
and are therefore simply variants of the granular form (
257,
290). Cytoplasmic contents, often containing organelles, may
invaginate and deposit filament- or vesicle-like membrane-bound
structures into the central vacuole (
65,
159,
160,
181,
235,
239,
252). The exact significance of this process is unclear,
although it has been postulated to be a mechanism of apoptotic
body deposition in
Blastocystis cells undergoing programmed
cell death (
254). The cytoplasm contains organelles typically
observed in eukaryotes. The features observable by transmission
electron microscopy (TEM) include one or more nuclei, Golgi
apparatus, endosome-like vacuoles, microtubules, and mitochondrion-like
organelles (Fig.
2 and
4). The organism is often surrounded
by a surface coat (Fig.
2B), sometimes referred to as the fibrillar
layer or capsule, of various thicknesses (
65). The surface coat
is often thicker in parasites freshly isolated from feces and
gradually thins out during prolonged laboratory culture (
40,
235), and cells without surface coats have been observed in
vitro (
65). The reason for this thinning out is unknown but
may be due to the postulated role of the coat in trapping bacteria
for nutritional purposes (
311,
314), which is not possible during
axenic culture, or may be unnecessary if nutrients provided
in laboratory culture are sufficient for growth. The surface
coat contains a variety of carbohydrates (
127,
258) and has
been postulated to play a role in trapping and degrading bacteria
for nutrition (
311,
314), protecting against osmotic shock (
40),
or to provide a mechanical barrier for functionally important
plasma membrane proteins from the immune system (
259).
The granular form resembles the vacuolar form except that granules
are present within the cytoplasm or, more commonly, within the
central vacuole of the organism (Fig.
1B and
2B and
5B). These
are more frequently observed in nonaxenized, older, and antibiotic-treated
cultures and have been described as being vacuolar forms containing
granules rather than as being a distinct parasite stage (
33,
233). The intracellular granules are heterogeneous and have
been described as being myelin-like inclusions, small vesicles,
crystalline granules, and lipid droplets (
65). Reproductive
granules within the central vacuole have been described and
have been reported to function in schizogony-like division (
220,
241,
319). Other authors argued that this cannot be accepted
due to the lack of evidence that these granules are indeed viable
and develop into
Blastocystis cells (
33,
233,
257,
290).
The amoeboid form (Fig. 1C and 2C) of Blastocystis spp. is rarely reported, and there are contradicting descriptions of what constitutes this morphological type. An early report described numerous amoeba-like forms in the diarrheal fluid of a patient who died of aspiration pneumonia (326). These cells were irregularly convoluted, and some cells possessed one or two large pseudopods. In another study, amoeboid forms from in vitro culture were observed to be 10 to 15 µm, possessing features typical of vacuolar forms, with the exception of one or two pseudopods (249). We have reported the presence of numerous amoeboid forms (Fig. 6) from Blastocystis colonies grown in soft agar (45, 252, 260, 261). Light microscopy and TEM showed cells with a central vacuole, a surface coat, and numerous Golgi bodies and mitochondria within the cytoplasmic extensions of pseudopods (252). Dunn et al. (65) previously described amoeboid cells ranging from 2.6 to 7.8 µm with extended pseudopodia and lysosome-like compartments containing ingested bacteria. In contrast to our studies, these forms lacked a central vacuole, a Golgi complex, a surface coat, and mitochondria (65). Considering the genetic diversity of the organism, it is plausible that the differing descriptions are due to genotypic variations among Blastocystis isolates. The presence of bacteria and bacterial remnants within the amoeboid form suggests a nutritional role for this form. The amoeboid form has been postulated to play a role in pathogenesis (115, 262, 264). However, the light and TEM micrographs in two of these reports (262, 264) were unconvincing for this form and appear more like irregularly shaped central vacuole forms, a common artifact of TEM processing. Despite the observation of pseudopod-like cytoplasmic extensions, the amoeboid form appears to be nonmotile. The identification of stage-specific molecular markers would be useful for studies of various developmental forms of the parasite and would obviate the problem of distinguishing the various forms by morphological criteria alone.
The cyst form (Fig.
1A and
3) is the most recently described
form of the parasite, and the late discovery is due to its small
size (2 to 5 µm), which can result in confusion with fecal
debris, and the observation that cysts are infrequently seen
in laboratory culture (
46,
153,
154,
234,
312). The cysts are
variable in shape but are mostly ovoid or spherical. The cyst
is protected by a multilayered cyst wall (Fig.
4), which may
or may not be covered by a loose surface coat (
153,
312,
313).
The cytoplasm of the cyst may contain one to four nuclei, mitochondria,
glycogen deposits, and small vacuoles (
5,
46,
153,
312). One
report (
237) described the presence of large multinucleate cysts
from the stools of
Macaca monkeys, which were 15 µm in
size, and this was suggested to be an indication of differences
among
Blastocystis species.
Blastocystis cysts were reportedly
able to survive in water for up to 19 days at a normal temperature
but are fragile at extreme temperatures and in common disinfectants
(
154). A later study (
306) showed that cysts could survive up
to 1 month at 25°C and 2 months at 4°C. The contrasting
viabilities among the studies may be due to isolate variations.
Vacuolar and granular forms, in contrast, are sensitive to temperature
changes, osmotic shock, and exposure to air (
146,
319). Experimental
infectivity studies of BALB/c mice, Wistar rats, and a variety
of bird species with the cyst form indicate that this form is
undoubtedly the transmissible form of the parasite. The formation
of in vitro-derived cysts by the incubation of vacuolar forms
in encystation medium was reported previously (
240,
241,
244,
282). These "cysts" appear to be curiously similar to the classical
granular forms, and the granules within the central vacuole
were reported to be reproductive in nature (
240,
241,
243).
It is likely that these are artifacts of culture induced by
the encystation medium, as they bear no morphological similarity
to the fecal cyst. Interestingly, in vitro-derived cysts are
able to infect Wistar rats (
244) and were apparently resistant
to osmotic lysis (
282).
Other forms have also been described, and these forms include
the avacuolar and multivacuolar forms. These forms reported
from TEM studies of fresh stool samples were significantly smaller
(5 to 8 µm) than culture forms and were suggested to be
the form that occurs in vivo (
233,
235). However, others observed
typical vacuolar forms from fresh fecal samples (
9,
64,
128,
132,
227,
232,
281,
318). The central vacuole was absent in
the avacuolar form, while the multivacuolar forms contained
multiple small vacuoles. The small size and distinct multivacuolar
or avacuolar morphology may be due to strain variations, or
they are possibly cells in various stages of encystation or
excystation, as similar morphologies were described in TEM studies
of cells undergoing excystation (
46,
153).
Life Cycle
Numerous conflicting life cycles have been proposed (
33,
217,
220,
233,
250,
319,
321), and these discrepancies are due largely
to the belief that
Blastocystis exhibits multiple reproductive
processes (
83,
220,
318). The suggestion that
Blastocystis undergoes
multiple fission has led to life cycles where schizogony is
one of the modes of reproduction (
220,
319). This and other
proposed modes such as plasmotomy (budding) (
263), endodyogeny
(
318), and sac-like pouches (
83,
242) are more likely due to
the pleomorphic nature of the organism and not true modes of
reproduction. A life cycle comprising thick- and thin-walled
cysts from multiple fission was proposed (
220). Those authors
hypothesized that the thick-walled cysts are important for external
transmission, while the thin-walled cysts were autoinfectious.
There is little scientific evidence to support such a proposal,
although schizogony-like reproduction in
Blastocystis has been
perpetuated in a number of authoritative sources, including
medical parasitology textbooks and the DPDx website of the Centers
for Disease Control and Prevention (
www.dpd.cdc.gov/dpdx/HTML/Blastocystis.htm).
Until proven otherwise, the only accepted mode of reproduction
is binary fission. The application of live-cell imaging technology
should provide a better understanding of the modes of reproduction
of
Blastocystis spp.
A revised life cycle (Fig. 7) must take into account the large reservoir of Blastocystis spp. among various animal populations and that humans are potential hosts to numerous zoonotic genotypes (subtypes). Upon ingestion of cysts, the parasite undergoes excystation in the large intestines and develops into vacuolar forms. Encystation occurs during passage along the large intestines and is deposited in the feces (152). The fecal cysts may be covered by a fibrillar layer that is gradually lost during cyst development (313).
Apart from a few studies, the transitions from one of the classically
described forms to another are not well understood. TEM studies
of the development of cysts to vacuolar forms were elegantly
demonstrated with a human isolate and a rat isolate (
46,
153).
In those reports, fecal cysts from both humans and rat develop
similarly and dramatically into vacuolar forms within 24 h of
inoculation into growth medium. In one of those studies (
153),
cells undergoing excystation apparently developed from cysts
into granular forms before becoming vacuolar in morphology.
Whether these granular forms are similar to those from patient
samples and laboratory culture is not known. In a separate study
(
317),
Blastocystis cysts enriched from a patient sample were
cultured in Jones medium and characterized by TEM at
24 h. The micrographs revealed that cell division of vacuolar
forms occurs while the parasite is still within the cyst wall
and that both granular and vacuolar forms were observed in the
same sample. Because only one time point was performed, it is
difficult to conclude the order in which these forms developed.
Certain culture conditions were reported to induce the development
of the granular form from the vacuolar form. These conditions
include old cultures (
250), axenization (
327), transfer to a
different culture medium (
235), and increases in serum concentrations
in the culture medium (
65,
130,
217,
321). Amoeboid forms probably
arise from vacuolar forms. Some evidence for this is seen when
vacuolar forms are cultured in agar, and after incubation, the
resultant colonies contain numerous amoeboid forms (
260,
261).

LABORATORY DIAGNOSIS
Microscopy
Blastocystis poses considerable challenges for the diagnostic
laboratory. Firstly, the uncertain pathogenesis of the parasite
discourages many clinicians from considering
Blastocystis to
be the etiological agent of disease. Secondly, the polymorphic
nature of the organism in wet mounts can result in confusion
with yeast,
Cyclospora sp., or fat globules. The classical vacuolar
forms may not predominate in fresh fecal specimens (
235), while
the smaller fecal cyst, when present, may be difficult to identify.
Direct microscopy is usually done with stained specimens. Multiple
stool specimens should be examined, since the parasite may exhibit
irregular shedding (
88,
281). Morphological features that may
aid in the laboratory diagnosis of
Blastocystis infection are
summarized in Table
2. Wet mounts with Lugol's iodine (Fig.
5D) and permanent-stained smears with acid-fast, Giemsa (Fig.
5E), Field's, and trichrome (Fig.
5F and G) stains have been
described, with trichrome being the most popular stain employed
(
8,
171,
175,
179,
210,
227,
270,
289,
307). Trichrome is a
routinely employed stain in many clinical microbiology laboratories,
and studies have shown that it is more sensitive for the detection
of intestinal protozoa than iodine-stained wet mounts (
71,
78,
117), and this is also the case for
Blastocystis spp. (
179,
270). However, short-term (24 to 72 h) in vitro culture increases
the sensitivity of detection compared to that of direct microscopy
of fecal smears stained with Lugol's iodine or trichrome (
135,
227,
270), although one study (
245) did not mentioned the use
of any staining method. However, in the case of mixed infections,
in vitro culture may favor the preferential amplification of
one subtype over another (
183,
295), although this was not seen
in another study involving a mixed infection (
227). In contrast
to in vitro culture, a number of reports indicated that the
formol ethyl acetate concentration technique (FECT) results
in very poor sensitivity for parasite detection (
227,
231,
245).
Subtype 3 was apparently associated with false-negative results
associated with this method (
227), although the reason for this
bias is currently unknown. This may explain a study in Thailand,
employing only formol ethyl acetate concentration, revealing
a prevalence of 0.19% for
Blastocystis isolates in primary school
children in central Thailand (
211). Another study using a number
of diagnostic approaches (simple smear, formol ether concentration,
Boeck and Drbohlav's Locke-egg-serum medium culture, and modified
acid-fast and modified trichrome staining) showed the prevalence
of
Blastocystis isolation to be 45.2% among Thai children in
the same region (
210). Present-day diagnostic laboratories should
also include the fecal cyst as an indicator of infection. If
necessary, these cysts can be selectively concentrated by density
gradient approaches to increase sensitivity (
309,
315). This
enrichment approach may be more practical in the research laboratory
setting since it may be cumbersome to perform during routine
diagnosis or in large-scale surveys. It was suggested that the
intensity of infection should be reported, and the general criteria
are whether five or more parasites are seen in a high-powered
field (
x400) for wet mounts (
77,
133,
166,
188,
194,
215,
319)
or under oil immersion (
x1,000) (
175,
179,
307) if permanent-stained
smears are used. Using this criterion and in comparison with
reports that do not use this criterion, accumulating studies
suggest a correlation between infection density and symptoms
(
51,
60,
67,
82,
85,
111,
116,
155,
165,
167,
175,
177,
215,
307). There are, however, a number of studies that reported
a lack of such a correlation (
63,
86,
131,
145,
180,
216). The
reason for this discrepancy is presently unclear but may be
due to genotype differences among
Blastocystis isolates or to
host factors such as age and genetic background variations in
the populations studied.
Laboratory Culture
Xenic or monoxenic laboratory cultures of
Blastocystis isolates,
which are cultures of
Blastocystis cells grown in association
with nonstandardized or single known species of microorganisms,
respectively, can be maintained in Jones (
110) or Boeck
and Drbohlav's inspissated egg (
30) medium. Jones medium
is the medium of choice in studies involving culture to identify
the parasite in patient samples (
135,
183,
227,
231,
245,
270,
291). There was one report (
183) on the inability to grow
Blastocystis isolates from Australian marsupials in Jones media, suggesting
that this medium may not support fecal cultures from certain
animal hosts. Other studies utilized diphasic agar slant medium,
which was useful for the culture of
Blastocystis isolates from
cattle, pigs, and chickens (
2-
4,
109,
110). Axenized cultures,
that is, cultures of
Blastocystis cells not associated with
any other living organism, display luxuriant growth in a variety
of media such as Iscove's modified Dulbecco's medium, minimal
essential medium, or biphasic inspissated egg slant overlaid
with Locke's solution (
98,
324). Cell densities of up to 2.5
x 10
7 cells/ml can be attained for monophasic medium (
98), while
slightly higher densities of approximately 6.0
x 10
7 cells/ml
were reported for cells cultured in biphasic inspissated egg
medium (
324). The doubling time of axenic isolates can be variable,
ranging from 6 to 23 h, depending on the isolate, study, and
type of medium used (
33,
324). Doubling times of approximately
50 h can be deduced from growth curves of
Blastocystis isolates
belonging to avian subtype 7 (
98,
169), and this may be due
to the nonoptimal incubation temperature, as avian hosts, particularly
chickens, generally have higher body temperatures than mammals.
The colony growth of
Blastocystis cells can be established in
soft agar (Fig.
6) using the pour plate method (
260,
261,
277),
and clonal growth was achieved with the addition of sodium thioglycolate
as a reducing agent (
260). The technique was useful as a step
toward the axenization of
Blastocystis isolates by physically
isolating parasite colonies from bacterial ones (
45,
164) and
for screening surface-reactive antibodies for cytotoxic activity
(
259).
Blastocystis cells are also able to grow on solid medium,
and parasite clones appear to be macroscopically similar to
bacterial colonies (
255). These cultures were viable for up
to 2 weeks and could be further expanded in liquid or solid
medium. Interestingly, for the same isolate grown in liquid
medium (
98), cultures reach maximal cell densities around 4
days postinoculation, enter death phase at day 5, and are subsequently
difficult to subculture. This indicates that the growth characteristics
of the same
Blastocystis isolate in solid medium are markedly
different from those of the isolate in liquid medium.
Axenic cultures of Blastocystis isolates are important for molecular and biochemical studies. Axenization can be achieved by the addition of antibiotic cocktails to eliminate contaminating bacteria and yeasts, and a variety of antibiotic mixtures have been described, with various levels of success (45, 128, 164, 269, 319). The process is generally laborious and may take weeks to months, and the successful elimination of microbial contaminants is not guaranteed. It has been suggested that some isolates require the presence of bacteria to survive, and therefore, the removal of all bacteria results in the death of the parasite (319). Lanuza et al. (128) previously described an improved method for Blastocystis axenization and managed to axenize 25 out of 81 isolates using a combination of Ficoll-metrozoic acid gradient and the addition of antibiotics. Cultures were initially treated with a basic antibiotic solution comprising 0.4% ampicillin, 0.1% streptomycin, and 0.0006% amphotericin B, and in subsequent subcultures, resistant bacteria were isolated and antimicrobial assays performed. The final stages of axenization involved the addition of antibiotics against remaining bacteria with density gradient enrichment for Blastocystis spp. The time required for axenization was approximately 3 weeks. In addition to antibiotic treatment, some authors noted improved success when physical methods were employed during axenization to separate parasites from the bulk of the bacterial load. This includes differential centrifugation (269), density gradient separation (128), and colony growth (45, 164). Such methods enrich for the parasite and provide a growth advantage. Chen et al. (45) noted that the axenization of Blastocystis would not have been possible without parasite enrichment via colony growth. There was a report on the use of micropipette manipulation to isolate Blastocystis clones from nonaxenic cultures of turkey cecal contents (95), and it would be interesting to investigate if this technique could be exploited as a step toward axenization.
Serology
Blastocystis infections lead to immunoglobulin G (IgG) and IgA
responses, as detected by indirect fluorescent antibody (IFA)
testing and enzyme-linked immunosorbent assay (ELISA) (
104,
112,
143,
323,
328). ELISA titers ranged from 1:50 to 1:1,600
(
328), and previously reported studies revealed that high titers
are associated with symptomatic infections (
104,
143,
323,
328).
Early ELISA studies showed that sera from patients harboring
Blastocystis spp. had high IgG titers against parasite extracts
(
323,
328). In one of the studies (
328), 30 sera from 28 patients
were tested: 3 were negative at the 1/50 threshold dilution,
8 were positive at 1/50, 3 were positive at 1/100, 2 were positive
at 1/200, 3 were positive at 1/400, 6 were positive at 1/800,
and 5 were positive at 1/1,600. Normal sera (42 blood bank sera)
were all negative at 1/50. Interestingly, IgA responses against
Blastocystis spp. could not be detected in the symptomatic population.
A recent study investigated the secretory IgA, serum IgA, and
serum IgG levels in
Blastocystis-positive individuals with and
without symptoms by ELISA (
143). This study showed that only
sera from symptomatic patients had significantly higher
Blastocystis-reactive
secretory IgA, serum IgA, and serum IgG levels than did sera
from asymptomatic carriers and healthy controls. In contrast,
Kaneda et al. (
112) showed by IFA that asymptomatic individuals
harboring
Blastocystis spp. possessed serum antibodies to the
parasite, although antibody titers were very low, and serum
dilutions greater than 1:60 failed to elicit a reaction. However,
the strongest reaction was seen in an individual with chronic
infection. It was suggested that constant exposure to the parasite
was necessary to elicit a serological response. The 1/50 ELISA
cutoff used in studies of symptomatic patients reported previously
by Zierdt and colleagues (
323,
328) is also rather low and suggests
that the parasite induces a weak immune response. However, considering
the genotypic (
53,
169) and antigenic (
122,
126,
156,
258,
298)
diversity among morphologically identical isolates, the low
values may be due to the choice of isolate used as the coating
antigen. Such antigenic variations may also explain the discrepant
observations among studies and must be taken into consideration
should a serological test kit be developed. Monoclonal antibodies
against
Blastocystis spp. have been described (
258,
298). The
majority of antibodies were IgM and localized to surface coat
antigens. These antibodies exhibited limited cross-reactivity
against different genotypes, indicating antigenic diversity
among
Blastocystis isolates (
253,
258). Although currently unavailable,
monoclonal antibodies specific for human-infective genotypes
would be useful for antigen detection studies, as was previously
described for
Entamoeba histolytica/
E. dispar (
283). Similarly,
the application of genotype-specific antigens in ELISA or immunofluorescence
formats should be useful for serological and epidemiological
studies.
Blastocystis-associated symptoms are generally self-limiting and may last between 1 and 14 days (63, 131, 307, 320, 329). However, some infections persist for months if left untreated (90, 94, 112, 131, 165, 175), and it is currently unknown if chronic infections influence seropositivity. A single study (112) of the serological response of Blastocystis-positive asymptomatic individuals showed that the highest IFA titer was obtained from a healthy individual infected with Blastocystis for 2 years. An ELISA study reported previously by Zierdt et al. (328) included two patients who provided sera within the first 2 weeks postsymptom and subsequently another sample at convalescence, about 6 weeks after onset. Comparison of acute-phase sera with convalescent-phase sera revealed an eightfold increase for one patient and a threefold increase for the other patient. Although large-scale studies are needed to validate these observations, results of those studies suggested that Blastocystis sp. does elicit an immune response, and both chronic and acute infections can result in significantly higher antibody titers than asymptomatic infections. Currently, considering our limited knowledge of the host immune response to Blastocystis spp. and the apparent antigenic diversity of the parasite, it is not practical to include serology in the routine laboratory diagnosis of Blastocystis, and it should be limited to epidemiological and serological studies.
Molecular Approaches
Molecular PCR-based diagnostic approaches for
Blastocystis identification
have been described. Subtype-specific diagnostic primers, also
referred to as STS primers, were developed from random amplification
of polymorphic DNA analysis of
Blastocystis isolates by Yoshikawa
et al. (
296,
297,
301), and these approaches amplified seven
distinct subtypes, which corresponded to different clades inferred
from ssrRNA. Such an approach has been shown to be useful for
epidemiological studies, providing information on the distribution
of various genotypes among human and animal populations (
2,
4,
138,
297,
304) and on the zoonotic nature of certain genotypes.
Other groups characterized isolates by PCR of ssrRNA followed by RFLP analysis (2-4, 31, 53, 202, 271, 291, 295, 305), dideoxy sequencing (183, 201, 227, 230, 231), or nested amplification of intragenic regions (270). PCR-RFLP analysis of the Blastocystis ssrRNA gene is commonly employed for prevalence studies, and a variety of primers for its amplification have been described (31, 53, 227, 291). However, major limitations of this approach are the lack of standardization of the conditions and choice of primers, mutations at restriction sites, and the difficulty in interpreting RFLP profiles from mixed infections. A high-throughput pyrosequencing technique for the rapid sequencing of the Blastocystis ssrRNA gene was described (230). This approach detects nucleotide polymorphisms in the gene and was able to genotype 48/48 Danish isolates in approximately 1 h but was unable to detect mixed-subtype infections. This approach would be extremely useful for large-scale epidemiological studies and for the rapid identification of genotypes during outbreak situations (87, 114, 123). A recent study compared the relative performances of various diagnostic methods for the identification of Blastocystis isolates (227). The FECT, permanent trichrome staining of feces fixed in sodium acetate-acetic acid-formalin, in vitro culture, and PCR approaches were compared using 107 samples from 93 patients with suspected enteroparasitic disease. The PCR approach was shown to be superior to the other approaches, and detection of Blastocystis-specific DNA was as sensitive as the culture method. This is in contrast to data from a study reported previously by Termmathurapoj et al. (270) that suggested that in vitro culture expansion was superior to direct PCR from stool samples. Another study (183) revealed that direct PCR from stool samples was superior to the culture method, with PCR detecting Blastocystis spp. in 35% of the samples, while the culture method detected 19%. The discrepancies observed in studies reported previously by Termmathurapoj et al. (270) and Parkar et al. (183) could be attributed to the fact that the latter involved the culture of feces from various animals in Jones medium, which did not support parasite growth, and that their DNA extraction method was more efficient. Other possibilities include the different specificities of the PCR primers employed for these studies (227). A method for the detection of Blastocystis spp. directly from unpreserved stool samples was described and provides a rapid diagnostic tool for Blastocystis identification (231). Primers specific for Blastocystis ssrRNA were able to detect greater than 32 parasites/200 mg stool artificially spiked with cultured parasites. In the evaluation of 43 clinical specimens, the PCR approach was tested against FECT and a culture technique, proving 100% test specificity and a significantly higher sensitivity than FECT. In that study, there were instances where culture-negative samples were PCR positive. This was attributed to the degeneration of parasites in the stool or to low numbers that prevented growth in vitro. Jones et al. (109) recently reported a method for the real-time PCR detection of Blastocystis spp. from stools. Primers specific to an undefined 152-bp region of the parasite genome was used for the assay and was able to amplify 11 laboratory-cultured isolates from the ATCC belonging to subtypes 1, 3, and 4. Results could be obtained within 3 h, with a detection limit of 760 cells per 100 mg of stool. Oddly, only three clinical samples were used in that study, and only one ATCC strain was spiked into Blastocystis-negative stool samples to determine sensitivity. For specificity determinations, those authors excluded only cross-reactions with bacterial but not protozoal pathogens. The assay was not able to distinguish among Blastocystis subtypes.
In summary, a variety of methods for the laboratory diagnosis of Blastocystis spp. exist. The FECT should be discouraged due to low sensitivity. Trichrome staining of direct fecal smears is sensitive, provides a permanent record of the specimen, and should be supplemented with information on whether five or more parasites are visible per oil immersion (x1,000) field. Other authors included more detailed reporting on parasite abundance (11, 85, 131, 179, 180) and quantified parasite abundance using terms such as rare (one to two parasites in every 10 high-power fields), few to moderate (one parasite in every one to five high-power fields), or abundant (five or more parasites per high-power field) (131). Such detailed reporting, beyond whether five or more parasites are present, is unnecessary since there is some controversy regarding correlation between infection density and disease. In instances of low parasite levels or when fecal cysts predominate in stool or environmental samples, in vitro culture is a useful method for diagnosis (245, 246). Direct wet mounts stained with iodine do not seem to add additional value to the diagnostic process, since trichrome-stained permanent smears have been shown to be more sensitive (179, 270). Considering current data, trichrome staining of direct smears coupled with stool culture in Jones medium, cost permitting, is the best approach for diagnosing Blastocystis infection in terms of specificity and sensitivity. Future laboratory diagnosis may need to include genotype information once a link between genotype and parasite pathogenesis is firmly established. For screening and epidemiological studies, PCR amplification of Blastocystis DNA from fresh stools or stool cultures is a convenient alternative to microscopy, and genotyping should also be included in the analysis. The development of real-time PCR for the sensitive and rapid detection of Blastocystis spp. with the ability to discriminate between multiple genotypes within a sample would be similarly advantageous for screening and epidemiological studies.

CLINICAL ASPECTS
Epidemiology and Prevalence
Authors of early studies lamented the lack of epidemiological
data on
Blastocystis spp. (
33,
233). However, recent years have
shown a dramatic increase in prevalence studies, and these studies
have shed light on the parasite's genotype distribution, mode
of transmission, and pathogenesis.
Blastocystis is an extremely ubiquitous parasite with a worldwide distribution (107, 250). It is not uncommon for it to be the most frequently isolated parasite in epidemiological surveys (15, 21, 51, 72, 94, 185, 210, 248, 287, 289). Prevalence varies widely from country to country and within various communities of the same country. In general, developing countries have higher prevalences of the parasite than developed countries, and this has been linked to poor hygiene, exposure to animals, and consumption of contaminated food or water. Prevalence can be low in countries such as Japan (0.5 to 1%) (96, 101) and Singapore (3.3%) (291) and high in developing nations including Argentina (27.2%) (25), Brazil (40.9%) (6), Cuba (38.5%) (70), Egypt (33.3%) (198), and Indonesia (60%) (185). In some countries, the carriage rate can be rather variable, depending on the subpopulation studied. Prevalence ranges of 1.9 to 32.6%, 0.19 to 45.2%, and 1.04 to 18.3% in prevalence studies from China (137), Thailand (210, 211), and Turkey (7, 56), respectively, have been reported. Such variations within the same country could reflect true differences between communities, especially if the same techniques were employed to identify the parasite. However, variations are also likely due to the use of different diagnostic approaches and the inherent difficulty in identifying stages other than the vacuolar form.
Recent surveys incorporated genotype information by PCR of Blastocystis DNA from feces or from stool culture. Such studies are now shedding light on the distributions of genotypes among human populations (Table 3) and animal hosts and also provide information on transmission routes or sources. A study by Yoshikawa et al. (304) employed the use of PCR-based genotype classification to study the distribution of Blastocystis genotypes among isolates from Bangladesh, Germany, Japan, Pakistan, and Thailand. The most dominant subtype among four populations except Thailand was subtype 3 (41.7 to 92.3%), followed by either subtype 1 (7.7 to 25%) or subtype 6 (10 to 22.9%). Similar genotype distributions in Singapore (78% subtype 3 and 22% subtype 1) (291), China (60.4% subtype 3 and 24.5% subtype 1) (137), Greece (60% subtype 3 and 20% subtype 1) (147), Germany (54% subtype 3 and 21% subtype 1) (31), and Turkey (75.9% subtype 3) (180) were also reported. In most studies, other genotypes were identified at lower frequencies (Table 3). Collectively, those studies suggest that subtype 3 is the subtype of human origin and that there is no correlation between Blastocystis geographic origin and genotype. It may be worthwhile to note that avian subtypes 6 and 7 may grow optimally at 40°C instead of 37°C, as is the case for the avian protozoan flagellate Histomonas meleagridis (84, 279). Isolates belonging to subtype 7 have longer doubling times, about 50 h, when cultured at 37°C (98). In this case, these slow-growing subtypes may still be missed during in vitro culture expansion of stool samples, resulting in an underrepresentation of such subtypes in epidemiological surveys. Although surveys revealed that the majority of individuals are host to a particular Blastocystis subtype, mixed infections in a minority of individual have also frequently been reported (31, 62, 137, 138, 180, 183, 227, 271, 294, 295). Depending on the study, mixed subtypes have been seen among 1.1 to 14.3% of samples surveyed. Most are coinfections with subtype 1 and subtype 3 (137, 138, 271, 294) while subtype 1/subtype 2 (137, 138), subtype 2/subtype 3 (137), and subtype 3/subtype 5 (295) combinations were infrequently reported. Intra-subtype 1 and -subtype 2 variations in ssrRNA sequence were also reported for single isolates (180, 227). It may be difficult to ascertain the true distribution of mixed infections in a particular individual, as this depends on the method employed to determine the Blastocystis subtype. Studies that genotype parasites after in vitro propagation (31, 62, 137, 138, 271) risk underestimating mixed infections since certain subtypes may outgrow others, as was shown recently (183, 295). Hence, genotyping of Blastocystis DNA obtained directly from stools may be more accurate for identifying mixed infections if PCR conditions are optimal. PCR employing subtype-specific STS primers is visually more discriminatory for mixed infections than is PCR-RFLP or sequence analysis of a single ssrRNA amplicon. In the former approach, the presence of bands corresponding to specific subtypes in agarose gels is immediately indicative of a mixed infection (295, 304), while in the latter two methods, mixed infections result in complicated RFLP profiles or mixed peaks in sequencing chromatograms (31, 183), which may be difficult to interpret.
Accumulating recent (2003 to 2008) epidemiological and other
studies suggest that
Blastocystis is pathogenic or associated
with a variety of disorders (
16,
22,
39,
47,
50,
67,
72,
85,
90,
91,
134,
143,
149,
150,
161,
168,
179,
184,
191-
193,
196,
205,
264,
293,
308). This is in contrast to reports that suggested
otherwise (
43,
131,
180,
274). Certain populations may be susceptible
to
Blastocystis-associated disorders, and risk factors include
immunocompromised health (
36,
51,
79,
173,
176,
196,
267,
308),
poor hygiene practices (
32,
55,
57,
85,
168,
171,
200,
208,
225), immigrants from and travelers to developing tropical countries
(
48,
51,
107,
216,
224), and exposure to animals or consumption
of contaminated food or water (
10,
25,
55,
57,
111,
134,
138,
166,
167,
175,
183,
200,
207,
208,
211a,
248). In a number of
recent surveys,
Blastocystis was reported to be found with higher
incidences in immunocompetent individuals suffering from intestinal
disorders than in the asymptomatic group (
67,
85,
116,
134,
149,
150,
168,
293). Interestingly, a recent survey showed a
high prevalence of
Blastocystis isolation in patients with allergic
skin disease (
179). Patients infected with human immunodeficiency
virus have a higher incidence of harboring
Blastocystis spp.
(
11,
36,
51,
72,
79,
91,
308). In a number of those studies
(
36,
51,
79,
308), the presence of the parasite was linked to
nonspecific symptoms including abdominal pain, diarrhea, and
flatulence (
51), although a report indicated that there was
no correlation between
Blastocystis infection and disease in
individuals infected with human immunodeficiency virus/AIDS
(
11). Higher incidences of
Blastocystis isolation were observed
in individuals under immunosuppressive therapy, such as renal
transplant patients (
176,
196) and children with nephrotic syndrome
receiving corticosteroids (
173). In a study of patients with
hematological malignancies undergoing chemotherapy-induced neutropenia,
Blastocystis was the most common parasite isolated, and infection
was linked to abdominal pain, diarrhea, and flatulence (
267).
Blastocystis infection is commonly seen in children from various
geographical settings, and accumulating epidemiological and
case studies suggest that
Blastocystis infection causes gastrointestinal
disease in this cohort (
13,
16,
35,
59,
85,
145,
149,
167,
221).
Collectively, there is an increasing body of evidence suggesting
that
Blastocystis is pathogenic or is an opportunistic pathogen,
with immunocompromised populations being more susceptible to
infection and its associated symptoms.
Blastocystis infections are common among certain occupations that involve exposure to animals, again reinforcing the zoonotic nature of the organism. These include food handlers (14, 57, 119, 200, 208) and animal handlers such as zookeepers and abattoir workers (183, 211a).
Longitudinal epidemiological studies add an important characteristic to point prevalence studies by permitting the characterization of temporal changes in affected patients and in disease characteristics, such as the frequency, complications, and outcomes of a disease. There are only a few such studies involving Blastocystis spp. (49, 94). An earlier study (49) involving young (10 to 28 months of age) Kenyan children over a 10-month period revealed a significant association between Blastocystis infection with unformed stools and diarrhea, while a later study (94) of Peace Corps volunteers in Guatemala over a 2-year period showed no correlation between Blastocystis infection and gastrointestinal symptoms. The discrepancy may be attributed to the different age groups studied or to geographical differences in Blastocystis genotypes.
An increasing number of prevalence studies have implicated contaminated water as being a source of Blastocystis infections (24, 25, 34, 68, 114, 118, 138, 162, 166, 167, 175, 248, 273, 285). This is not surprising since the transmissible form of the parasite is the water-resistant cyst (154). In a study involving a Thai army population, Blastocystis was found to be the most common (21.9%) intestinal parasite (248). This high prevalence among the soldier population was significantly linked to the consumption of unfiltered or nonboiled water. A recent study (138) involving the use of STS primers on stool samples of 238 randomly selected individuals from a village in Yunnan province, China, revealed high infection rates (32.6%). It was observed that the consumption of raw water plants was associated with subtype 1 infections, while drinking unboiled water was associated with subtype 3 infections. This was the first study to investigate the association between subtypes and transmission routes, although more studies are needed before any firm associations can be made.
One of the key questions in Blastocystis biology is whether disease is genotype related. A few studies have been carried out to address this issue, although the results have been equivocal. A study by Kaneda et al. (113) employed PCR-RFLP ribotyping on Blastocystis spp. isolated from asymptomatic individuals and patients with gastrointestinal symptoms. Their results suggested that ribodemes I, III, and VI (subtypes 1, 4, and 2, respectively) were associated with symptoms, with colonoscopic evidence of inflammation in patients harboring ribodemes III and VI. Ribodeme II (subtype 3), which was the most commonly isolated genotype, was not associated with symptoms. In a similar study, genotyping was carried out with isolates of 28 patients with gastrointestinal disorders and 16 asymptomatic individuals (105). Subtype 1 was found exclusively in symptomatic patients, while subtypes 3 and 6 were found in both groups. Subtype 7 was found only in asymptomatic individuals. Those authors concluded that subtype 1 was the most virulent, while subtypes 3 and 6 consisted of pathogenic and nonpathogenic strains. A study of isolates from China revealed an association between subtype 1 and disease, while subtype 3 was isolated predominantly from asymptomatic individuals (294). Tan et al. (265) employed arbitrary primed PCR on Blastocystis DNA and were able to distinguish among isolates obtained from eight symptomatic and eight asymptomatic isolates. In contrast, other studies indicated no association between disease and parasite genotype (31, 304). Böhm-Gloning et al. (31) analyzed 158 isolates by PCR-RFLP and determined that the study population was infected by five subgroups (genotypes), none of which was significantly correlated with intestinal disease. A study involving isolates from asymptomatic and symptomatic individuals from Bangladesh revealed no association between genotypes and disease, although only 26 samples were analyzed (304). In a recent case study, Blastocystis sp. subtype 8 was isolated from a Danish woman suffering from diarrhea, abdominal pain, bloating, and flatulence. No other infectious cause was evident, and her symptoms subsided after a course of trimethoprim-sulfamethoxazole (TMP-SMX) therapy (228). A recent study among Blastocystis isolates from a Turkish hospital revealed the presence of subtypes 1, 2, and 3 among adult and pediatric patients (62). Only subtype 2 showed a statistically different distribution between asymptomatic and symptomatic patients, with a greater proportion within the asymptomatic group. One reason for the discrepant conclusions on subtype association with disease is how the data were interpreted. Most authors seek statistical differences in subtype distribution between asymptomatic and symptomatic groups (31, 62, 180, 294, 304), while others consider the possibility that pathogenic subtypes can be present in approximately equal numbers in either group, possibly due to intrasubtype variations (105) or the presence of pathological evidence within the symptomatic group (113). Due to these complications, Dogruman-Al et al. (62) suggested that it is clearer to identify nonpathogenic subtypes since these subtypes should consistently be found in greater proportions within the asymptomatic group. Indeed, more studies with larger sample sizes are needed before this issue is resolved. Genotyping of isolates during outbreak situations may provide a valuable opportunity to identify pathogenic subtypes. The possibility of intrasubtype variation in pathogenesis should also be considered, as was suggested previously (105, 113). Collectively, studies suggest that at least subtype 1 is associated with disease, while subtypes 2 and 3 may be nonpathogenic.
Infection and Disease
Signs and symptoms.
An earlier report by Clark (
53) indicated that there are about
equal numbers of studies that either implicate or exonerate
Blastocystis spp. as a cause of disease. This balance has tipped
dramatically over the last decade, with evidence accumulating
from epidemiological, in vitro, and animal studies strongly
suggesting the pathogenic potential of the parasite. Clinical
features of illness that have been attributed to
Blastocystis spp. are nonspecific and include nausea, anorexia, abdominal
pain, bloating, flatulence, and acute or chronic diarrhea. Of
these features, the most commonly recorded symptoms among patients
are abdominal pain and diarrhea (
67,
116,
245,
267). Symptoms
can be variable, ranging from mild diarrheal illness (
90) and
chronic diarrhea (
205) to acute gastroenteritis (
16,
136,
161).
A number of studies suggested that the finding of greater than
five parasites per high-power field (
x400) or, less commonly,
oil immersion (
x1,000) objective is associated with the acute
presentation of gastrointestinal symptoms (
51,
67,
82,
85,
111,
116,
155,
165,
167,
177,
215), while one study described an
association between infection density and allergic cutaneous
diseases (
80). In a study of
Blastocystis-positive patients
from a Turkish hospital, the criteria for selection were the
absence of any other coinfecting pathogens and the presence
of more than five parasites per high-power field (
116). The
symptoms from this group were abdominal pain (76.9%), diarrhea
(50%), distention (32.6%), and urticaria (5.7%), suggesting
an association between parasite density and pathology. Other
signs and symptoms associated with
Blastocystis infections include
fecal leukocytes (
60,
89,
116,
206,
208,
280), eosinophilia
(
75,
124,
161,
215,
280,
307), and cutaneous rashes, particularly
urticaria (
19,
28,
278).
There are no reports of Blastocystis-associated dysentery, and it appears that the parasite is generally noninvasive, as indicated by endoscopy (43, 76, 329, 330) and histology of experimentally infected animals (5, 152, 187). An interesting case study described Blastocystis trophozoites present in the liver abscess aspirate of a 63-year-old man with a 5-day history of fever and blood-tinged watery diarrhea (102). Blastocystis was also present in stools, while E. histolytica could not be detected, suggesting an invasive extraintestinal Blastocystis infection. This was subsequently ruled out, as serology indicated high titers of E. histolytica antibodies, which subsided following metronidazole treatment, and because E. histolytica DNA was detected by PCR in the liver aspirate. Those authors concluded that the patient suffered amebic dysentery and liver abscess, with the latter being coinfected with Blastocystis. The findings of that study indicated that extraintestinal infections with Blastocystis spp. may occur, with invasion mediated by some other pathogen. Fecal leukocytes, when present, are indicative of inflammatory diarrhea, which may be due to infectious and noninfectious etiologies such as inflammatory bowel disease and infections with Clostridium difficile, Salmonella spp., and Shigella spp. (23, 172, 212, 213). Some studies reported the presence of fecal leukocytes in symptomatic patients suffering from Blastocystis-associated diarrhea (60, 89, 116, 206, 208, 280), while others did not observe such an association (81, 275, 329). There is currently little evidence to suggest that Blastocystis infection results in or is associated with inflammatory diarrhea (157), and if fecal leukocytes are present, other possible causes should be pursued. Two studies reported an association between Blastocystis infection and the presence of Charcot-Leyden crystals in stools (14, 161). Charcot-Leyden crystals are breakdown products of eosinophils, and their presence in stools is traditionally associated with E. histolytica infections (73). The significance of Charcot-Leyden crystals in Blastocystis infections is presently unclear, although an undetected E. histolytica infection could have resulted in such an observation, since mixed infections with Blastocystis and E. histolytica are not uncommon (102, 144, 171, 197, 215).
Accumulating reports also suggest an association between Blastocystis and irritable bowel syndrome (IBS), a functional bowel disorder in which abdominal pain is associated with a defect or a change in bowel habits (82, 104, 144, 293). In two studies (82, 293), Blastocystis was detected more frequently in IBS patients than in a control group consisting of IBS-negative patients with gastrointestinal symptoms. A serological study revealed significantly higher IgG2 levels against Blastocystis in IBS patients who were both stool positive and negative for the parasite (104). Those authors suggested that carbohydrate antigens of the parasite were responsible for the increase in IgG2 levels. In contrast, others found no correlation between Blastocystis infection in IBS patients and that in controls (274). The current data suggest an association between the parasite and IBS, although it cannot currently be concluded that it is the etiological agent of the disease, since an abnormal intestinal condition may provide an environment in which the parasite can thrive (275).
Parasites have been known to be associated with allergic cutaneous lesions, particularly urticaria. Helminths including Strongyloides stercoralis, Ascaris lumbricoides, Anisakis simplex, and Trichuris trichiura have been reported to exhibit a direct relationship with chronic urticaria (80). Among the protozoa, there is some evidence linking G. intestinalis with urticaria (80). Interestingly, accumulating case reports also suggest a causal link between Blastocystis and cutaneous lesions (19, 28, 39, 90, 115, 120, 148, 184, 278). In those studies, the presence of the parasite was seen concurrently in patients with acute or chronic urticaria (19, 28, 115, 278), delayed-pressure urticaria (39), angioedema (148), and palmoplantar pruritis (120). Treatment of the parasite leads to the resolution of both the infection and cutaneous lesions. The concept of luminal protozoa as being causative agents of allergy-like cutaneous lesions is interesting and has been suggested to be linked to the activation, by parasite molecules, of certain specific immune cell subsets such as interleukin 3 (IL-3)-, IL-4-, IL-5-, or IL-13-secreting Th2 cells, which mediate IgE allergic responses (184). It was also suggested that Blastocystis molecules may activate the complement pathway with the generation of anaphylotoxins C3a and C5a. The interactions of these molecules with mast cells and basophils induce histamine release and subsequent related skin disorders (278). Some studies suggested an association between Blastocystis infection and the use of nonsteroidal anti-inflammatory medications, although the significance of this association is unknown (28, 90). A recent study revealed that acute urticaria was associated with amoeboid forms belonging to subtype 3 (115). Future studies should investigate the presence of Blastocystis-specific IgE as an indication of parasite-specific allergic responses. The possibility of IgE-independent allergy mechanisms also exists and should be considered (278), since some studies showed that patients with Blastocystis-associated urticaria have IgE levels within the normal range (39, 80, 115, 184, 278). Eosinophils were recently postulated to play a direct role in the pathology of urticaria (226), and it may be interesting to investigate if there is any association between Blastocystis and eosinophil-mediated urticaria. Taken together, those studies suggested that Blastocystis can cause a variety of disorders not necessarily confined to the intestinal tract. In this regard, the presence of Blastocystis infection in patients with urticaria indicates a causal role of the parasite, and appropriate chemotherapy should be considered.
Pathogenic potential.
Among the studies that purported a lack of association between Blastocystis infection and intestinal disease, many of them focused on the distribution of the parasite between symptomatic and asymptomatic individuals (11, 43, 81, 94, 131, 216, 247, 275). Such studies indicated either no significant difference between the prevalences of the parasite in either group (11, 94, 131, 216, 275) or a higher prevalence in asymptomatic individuals (43, 81, 247). Leder et al. (131) conducted a case-controlled study in a cohort of 2,800 people and concluded that there was no correlation between clinical symptoms and Blastocystis infection in immunocompetent individuals. This finding was based on the following observations. In the absence of any enteric pathogen, Blastocystis was detected without significant differences between asymptomatic and symptomatic groups. Symptoms did not correlate with parasite abundance, and individuals were likely to harbor Blastocystis isolates during both symptomatic and asymptomatic periods. Such conclusions are based on the assumption that the parasite is biologically homogenous, and therefore, if pathogenic, more symptomatic individuals would harbor the parasite than asymptomatic ones. However, these assumptions do not imply that Blastocystis is nonpathogenic since infections with other established enteric protozoan pathogens do not always lead to disease. Most Giardia (approximately 60%) and E. histolytica (approximately 90%) infections are asymptomatic or mildly symptomatic in immunocompetent individuals, and only a minority of infections lead to intestinal disease (26, 103, 178). Furthermore, a number of asymptomatic E. histolytica carriers may subsequently develop intestinal disease (121), and this may also be true for Blastocystis. The asymptomatic state also appears to be common for Cryptosporidium infections based on the high frequency of seroconversion compared to that of clinically diagnosed disease (74, 125, 190). Studies of these pathogens revealed that clinical outcome is multifactorial, influenced by host and parasite factors, and it may therefore be difficult to predict pathogenic potential even from case-controlled studies. As such, studies that do not show a significant difference between the occurrence of Blastocystis spp. in asymptomatic populations and the occurrence in symptomatic populations cannot be used as an argument that the parasite is nonpathogenic. In recent years, a number of studies focused on Blastocystis infections in symptomatic individuals in the absence of coinfecting enteric pathogens (116, 140, 161, 165, 177, 205). All those studies revealed the resolution of symptoms upon antiprotozoal treatment with the concomitant eradication of the parasite (Table 4). Currently, there have been two reports on the placebo-controlled treatment of Blastocystis-positive symptomatic patients, with both studies showing that chemotherapy was successful in both clinical cure and eradication of the parasite (165, 205). Nigro et al. (165) conducted a placebo-controlled treatment trial of Blastocystis infection with metronidazole to evaluate the drug's efficacy in inducing clinical remission and parasite clearance in immunocompetent individuals with Blastocystis infection as the only cause of diarrhea. Out of 616 subjects with diarrhea, 76 patients were infected with Blastocystis spp. in the absence of other infectious or noninfectious causes of diarrhea. Of these patients, 40 were assigned to the treatment group and 36 were assigned to the placebo group. After therapy, 35 of 40 (88%) patients in the treatment group reported clinical cure, with parasitological clearance in 32 cases (80%), whereas only one case (3%) in the placebo group achieved intestinal clearance of Blastocystis. In the other placebo-controlled study, Rossignol et al. (205) investigated the efficacy of nitazoxanide for the treatment of diarrhea and enteritis with Blastocystis as the sole identified pathogen. The results indicated that in contrast to the placebo group, the drug was effective in the resolution of symptoms, with parasite eradication in the nitazoxanide-treated group. A recent study (116) investigated the effect of metronidazole on 52 individuals infected with Blastocystis spp. in the absences of other enteric parasites or bacterial pathogens. Intestinal symptoms were evident in 46 of 52 (88.4%) of these patients. Out of 41 individuals who submitted a second stool specimen after metronidazole therapy, 39 reported eradication of the parasite, with clinical cure in 36 of the 39 (92.3%) patients. Intestinal symptoms persisted in the remaining two individuals, who failed to respond to chemotherapy. A study by Ok et al. (177) investigated the effect of TMP-SMX on Blastocystis-positive patients. Fifty-three symptomatic patients harboring Blastocystis spp. as the sole evident cause of diarrhea were treated with TMP-SMX for 7 days. The parasite was eradicated in 50 of 53 (94.3%) patients, with clinical symptoms disappearing in 39 (73.6%) patients and decreasing in 10 (18.9%) patients, and no change was observed in one (1.9%) patient, whereas symptoms persisted in all three patients in whom Blastocystis infection could not be eradicated.
View this table:
[in this window]
[in a new window]
|
TABLE 4. Studies of treatment and outcome of symptomatic individuals harboring Blastocystis as the sole identified pathogen
|
Studies of therapeutic improvement concomitant with parasite
clearance in symptomatic patients with
Blastocystis infection
as the only evident cause of disease are compelling for a pathogenic
role of the organism. However, there are a number of caveats
to such a conclusion. The drugs used in these studies, metronidazole,
nitazoxanide, and TMP-SMX, are all broad-spectrum antibiotics,
and clinical cure may have been attributed to some as-yet-unidentified,
missed, or occult microbial enteric pathogen. Secondly, some
studies did not include a comprehensive exclusion of possible
enteric pathogens, especially viruses or bacterial toxins (
116,
177,
205), which may have contributed to the reported symptoms.
A major gap in our understanding of
Blastocystis pathogenesis
is the inability to fulfill Koch's postulates. Recent studies
suggested that rats and chickens are good candidates as animal
models (
105,
106,
266,
306), and future studies should focus
on the pathology and transmissibility of
Blastocystis spp. in
these hosts. The use of
Blastocystis-specific inhibitors such
as cytotoxic monoclonal antibodies (
253,
254) in these animal
models would be an invaluable strategy to investigate if there
is a correlation between infection and disease, as these would
circumvent the broad-spectrum effects of drugs commonly administered.
Taking into account that there are no reports that unequivocally
prove that
Blastocystis is nonpathogenic and that there are
accumulating studies that indicate otherwise, it would be prudent
to consider
Blastocystis to be an emerging protozoan pathogen.
Treatment should be administered for acute and chronic cases
when all other possible infectious or noninfectious etiologies
have been excluded.
Animal Studies
A major obstacle to our understanding of
Blastocystis pathobiology
is the absence of a good animal model in which to test Koch's
postulates. A variety of experimental infection studies involving
rats, mice, guinea pigs, and chickens have been described (
5,
105,
106,
151,
152,
182,
187,
244,
266,
306). An early study
showed that germ-free guinea pigs were susceptible to
Blastocystis infections via oral and intracecal inoculations (
187). Heavy
infections led to diarrhea and gross cecal hyperemia. A later
study involved the experimental infection of young (less than
8 weeks old) BALB/c mice with
Blastocystis (
152). Infections
were generally self-limiting, although some mice showed weight
loss, and histological examination revealed inflammatory responses
and mucosal sloughing. The mild and self-limiting nature of
this infection may be due to the low pathogenic potential of
this particular isolate or the possibility that mice in general
may not be good hosts for
Blastocystis. Surveys have shown that
laboratory mice generally do not harbor
Blastocystis, while
rats and domestic fowl, particularly chickens, are often infected
with the parasite (
44,
132). Subsequent experimental infection
studies focused on rats and chickens as hosts and potential
animal models (
105,
106,
266,
306). Those studies showed that
the cyst is the transmissible form of the parasite and that
as few as 10 to 100 cysts are sufficient to establish an infection
(
266,
306). Studies have shown that isolates from a guinea pig
and a laboratory rat can infect Wistar rats (
306) and that isolates
from chickens, quails, and geese easily infect chicks (
266).
More recently, the infectivity of various zoonotic
Blastocystis genotypes from humans was tested in rats and chickens (
106).
There was variability in the infectivity of the isolates in
relation to rodent subtype 4 and avian subtype 6. Interestingly,
subtype 3, a possible human isolate, could not infect chickens
and rats, while avian subtype 7 could infect only chickens,
suggesting that these subtypes have a restricted host range.
In another study, isolates from asymptomatic and symptomatic
patients were genotyped and used for experimental infections
in rats (
105). Interestingly, isolates from symptomatic patients
induced moderate to severe pathological changes in infected
rats, while isolates from asymptomatic individuals induced mild
pathology. Those authors concluded that subtype 1, which induced
25% mortality in rats, was pathogenic, while pathogenic and
nonpathogenic variants exist among subtypes 3 and 4. This is
the first study to correlate
Blastocystis genotypes with virulence
in a laboratory animal and suggests that rats are good animal
models for the study of
Blastocystis pathobiology. However,
the observation that variations in host specificity may exist
for different
Blastocystis subtypes may limit experimental infection
studies using rats (
106). Hence, the lack of pathology may reflect
resistance to colonization in the rat rather than a nonpathogenic
role of the parasite. More studies are urgently needed to validate
the roles of various genotypes in intestinal disease.
In Vitro Studies
Cytopathic effects on host cells.
A few studies have sought to investigate the effects of
Blastocystis spp. on mammalian cell cultures (
139,
191,
192,
286). Cells
and lysates of
Blastocystis spp. isolated from asymptomatic
carriers and symptomatic patients induced cytopathic effects
on Chinese hamster ovary cells but not in HT-29 colonic epithelial
cells (
286). The lack of cytopathic effects on HT-29 was validated
in a later study, which was also absent in T-84 cell lines exposed
to
Blastocystis (
139). However, it was observed that 24 h of
incubation of these colonic epithelial cells lines with
Blastocystis induced the production of proinflammatory cytokines IL-8 and
granulocyte-macrophage colony-stimulating factor. At 6 h of
incubation,
Blastocystis cells did not induce IL-8 production
but reduced the
Escherichia coli- or lipopolysaccharide-induced
secretion of IL-8. Those authors suggested that
Blastocystis is able to modulate the host immune response, and at initial
stages of infection, the parasite may downregulate the host
immune response to improve survival, as was demonstrated for
Toxoplasma gondii (
58) and
Cryptosporidium parvum (
129). Our
laboratory recently showed that
Blastocystis ratti (subtype
4) cysteine proteases induced IL-8 production from T-84 cells
in an NF-

B-dependent manner (
191). Besides a proinflammatory
role, the upregulation of NF-

B can also be a mechanism to enhance
replication, survival, and dissemination of the parasite within
the host (
268). Sustained NF-

B activation has been shown to
increase the expression of antiapoptotic molecules, hence preventing
the death of host cells, which may allow the pathogen to replicate
(
268). Whether this phenomenon operates in
Blastocystis-host
interactions or if various subtypes modulate host responses
differently is unknown, and this should be investigated. The
exposure of intestinal epithelial cells to
Blastocystis sp.
subtype 4 led to limited apoptosis not associated with compromise
in host cell barrier function (
192), suggesting that the parasite
may exert an antiapoptotic effect on host cells. We recently
reported a systematic in vitro study to investigate the effect
of
Blastocystis ratti (subtype 4) on a rat intestinal epithelial
cell line (IEC-6) (
192). The assays were carried out using Millicell
cell inserts, which facilitated the study of contact-independent
effects on host cells via parasite secretions. The exposure
of IEC-6 cells to
Blastocystis induced apoptosis in a contact-independent
fashion. Host cells also revealed F-actin distribution, a loss
of transepithelial resistance (TER), and increased permeability.
The inhibition of apoptosis did not rescue cells from TER loss
and increased permeability, suggesting that apoptosis may not
play a major role in barrier function compromise. Metronidazole
was able to abrogate TER loss and increased permeability, indicating
that live parasites were required to mediate these adverse effects
and also suggesting the therapeutic role of the drug in vivo.
Those authors proposed that barrier function compromise, evidenced
by TER and permeability assays, is related to
Blastocystis-associated
diarrhea. Taking into account the genotypic and antigenic diversity
of the parasite, more studies should be carried out on a range
of
Blastocystis subtypes and their effects on colonic cell lines.
Cysteine proteases as virulence factors.
Cysteine proteases of parasitic protozoa have been implicated in a number of important biological functions including the invasion of host cells, immune evasion, pathogenesis, and virulence (209). Like most other protozoan parasites, Blastocystis contains predominantly cysteine proteases, evidenced by sensitivity to the inhibitors iodoacetamide and E-64 in azocasein assays (191, 222), and these localize to the parasite central vacuole (191). Parasitic lysates of Blastocystis isolate B (subtype 7) were found to have high protease activity, and nine protease bands of low (20 to 33 kDa) and high (44 to 75 kDa) molecular masses were reported in sodium dodecyl sulfate-polyacrylamide gel electrophoresis gelatin assays. Proteases were found to be pH dependent, and the highest proteolytic activity was observed at neutral pHs (222). Blastocystis lysates and spent medium were able to degrade human secretory IgA, the predominant immunoglobulin defense at the mucosal surface (193). Two isolates were investigated, and it was observed that B. hominis isolate B (subtype 7) and B. ratti (subtype 4) cleaved secretory IgA with cysteine and aspartic protease activities, respectively. This suggests that Blastocystis proteases are virulence factors and contribute to parasite survival in vivo by degrading neutralizing mucosal antibodies. The in vivo role of IgA in mucosal defense against Blastocystis is unknown, although a serological study (143) showed significantly higher secretory IgA levels in symptomatic individuals with Blastocystis infections than in asymptomatic carriers and healthy individuals. Secretory IgA has been shown to be important for the control and host eradication of Giardia (66, 103), evidenced by the inability of IgA-deficient mice to clear experimental infections. Blastocystis does not readily colonize mice (44), and although rats can be experimentally infected with Blastocystis, IgA-deficient rats have not been described in the literature. However, IgA-deficient chickens have been described (141, 272), and it would be interesting to investigate the role of IgA using chickens, since chickens can be experimentally infected with Blastocystis (106). Additionally, longitudinal epidemiological studies focusing on the persistence of Blastocystis infection in individuals suffering from selective IgA deficiency may shed light on the pathogenesis of the parasite. Cysteine proteases from live Blastocystis parasites and lysates were shown to mediate IL-8 secretion from T-84 colonic epithelial cells in an NF-
B-dependent manner. This was evidenced by the protease-induced nuclear translocation of NF-
Bp50 and the transcription, expression, and secretion of IL-8 (191). Those authors proposed that in vivo, Blastocystis-mediated intestinal epithelial cell production of IL-8 causes an influx of inflammatory cells into the intestinal mucosa with resultant tissue damage and gastrointestinal disturbances. It was reported that the invasion of the intestinal epithelium by pathogens is not necessary for the induction of inflammation (27), and since Blastocystis is a noninvasive parasite, secreted products from the parasite might initiate the inflammatory process by activating cell surface receptors. Pathogenic E. histolytica cells produce the extracellular release of 10- to 1,000-fold more cysteine proteases than the noninvasive E. dispar (199). It would be worthwhile to study the relative protease levels among the various Blastocystis subtypes and to investigate if there is a similar correlation between protease activity and virulence. Most parasite cysteine proteases that have been characterized fall into clan CA (papain-like). These are assigned to various clans by a number of characteristics including sequence homology directly spanning the catalytic cysteine and histidine (209). The cysteine protease of Blastocystis should accordingly be further classified into their respective clans and families to obtain a clearer picture of their biological functions.
Current in vitro studies support a pathogenic role for Blastocystis. Parasite secretory components, such as cysteine proteases, may exert a variety of detrimental effects on host cells, resulting in cytopathic effects, barrier compromise, and the production of proinflammatory cytokines (Fig. 8).
Treatment
The need to treat individuals infected with
Blastocystis is
equivocal, considering the controversial pathogenesis of the
organism and the apparent self-limiting nature of symptoms (
11,
20,
63,
131,
238,
284,
307,
320,
329). In instances where treatment
is warranted, metronidazole is the most frequently prescribed
antibiotic (
39,
155,
161,
165,
267,
278). Various drug regimens
for metronidazole have been prescribed, ranging from 250 to
750 mg three times a day for 10 days (
155,
161,
278) to 1.5
mg/day for 10 days (
39,
165,
267), or used in combination with
other drugs such as paromomycin (
184) or cotrimoxazole (TMP-SMX)
(
16). A placebo-controlled treatment trial was carried out in
order to evaluate the efficacy of metronidazole treatment in
inducing clinical remission and parasitological eradication
in immunocompetent individuals with
Blastocystis infection as
the only evident cause of diarrhea (
165). The data suggested
that
Blastocystis induced intestinal disease and responded to
metronidazole treatment. In another study involving 28 individuals
severely infected with
Blastocystis spp. (
155), 12 were administered
metronidazole at 250 to 750 mg three times/day for 10 days,
while 9 patients were administered one tablet of cotrimoxazole
(TMP-SMX) three times/day for 10 days. Eradication was observed
in 4 of the 12 and 2 of the 9 patients treated with metronidazole
and cotrimoxazole, respectively, indicating treatment failure
in some patients with severe
Blastocystis infections, possibly
due to drug resistance. Studies have shown that
Blastocystis strains isolated from patients may exhibit differences in sensitivity
to metronidazole (
92,
292,
316), ranging from 0.01 to 5 mg/ml,
depending on the study. A report of isolates from IBS patients
revealed 60% resistance to 0.1 mg/ml of metronidazole (
292).
Another study of isolates from different geographical locations
reported an Indonesian isolate showing resistance at 1.0 mg/ml
metronidazole (
92). The cyst form has been shown to be resistant
(up to 5 mg/ml) to the cytotoxic effect of the drug (
316). Those
observations, together with the extensive genetic heterogeneity
of the organism, may offer explanations for the variability
in drug susceptibilities and treatment failures.
Studies to investigate the usefulness of cotrimoxazole in Blastocystis infections have been carried out (155, 177). Ok et al. (177) observed that the drug eradicated Blastocystis infections and resolved or decreased symptoms in over 90% of the cohort. In contrast, a study by Moghaddam et al. (155) showed only 22% (two of nine patients) eradication of the parasite in Blastocystis-infected individuals. Nitazoxanide, a 5-nitrothiazole broad-spectrum antiparasitic agent, has been reported to be effective against Blastocystis (50, 61, 205). A placebo-controlled study revealed that 36 (86%) of the 42 Blastocystis-infected patients who received nitazoxanide showed resolution of symptoms, compared with 16 (38%) of 42 patients who received placebo, with a concurrent absence of the parasite in stool samples.
Paromomycin, a broad-spectrum antibiotic indicated for acute and chronic intestinal amoebiasis, was shown to successfully treat Blastocystis infections associated with cutaneous lesions, predominantly urticaria (19, 120, 184, 278). Treatment failure was suspected for one of three patients in one study, who was subsequently successfully treated with metronidazole (278). Curiously, an early in vitro study to investigate the susceptibilities of four axenic strains of Blastocystis to a variety of drugs revealed that paromomycin was not inhibitory to the parasites (325). This suggests that the drug acts by destroying bacterial flora necessary for the parasite's growth. Alternatively, this discrepancy may reflect genotype variations of Blastocystis in the drug's killing effects, and there is therefore a need to reevaluate all in vitro sensitivity studies, case studies, and treatment trials in relation to the actual genotype exposed to the drug.
In summary, a variety of drug treatment options are available for Blastocystis infections (Table 5), and metronidazole appears to be the most effective drug for Blastocystis chemotherapy despite some evidence for treatment failures (75, 155, 288). In such circumstances, cotrimoxazole and nitazoxanide may be considered as second-choice drugs. Treatment should be considered if diarrhea is persistent and no other pathogen apart from Blastocystis is identified in fecal specimens. Future studies should investigate if there is an association between genotype and variations in drug sensitivity and should also focus on the mechanism(s) of action of and resistance to metronidazole.

CONCLUSIONS
The authors of the last extensive review on
Blastocystis, which
was published in 1996 (
233), wrote in their conclusion, "Our
current knowledge of
Blastocystis hominis and the putative disease
it causes is insufficient to determine the significance of the
parasite in humans." In the 12 years since, our knowledge of
this interesting parasite has increased tremendously. The term
B. hominis is no longer applicable to all human isolates, since
we now know that humans can be infected by numerous genotypes,
many of which are zoonotic. Hence, laboratories should report
the presence of the parasite from patient samples as being
Blastocystis sp. instead of
B. hominis and, in addition, include details
on whether five or more parasites are observed per oil immersion
(
x1,000) field. A standardization of
Blastocystis terminology
to improve communication and correlate research results has
been proposed. All mammalian and avian isolates are designated
Blastocystis sp. and assigned to one of nine subtypes (
229).
Current data suggest that subtype 3 is the only subtype of human
origin and, therefore, is the true
B. hominis. Laboratory rats
or chicks appear to be good candidates for the development of
an animal model, and major efforts should be directed at this
endeavor. Once this is achieved, issues pertaining to pathogenesis,
life cycle, and roles of various stages can be better addressed.
Our understanding of
Blastocystis biology will accelerate once
genome information is available, as has been the case for other
parasitic protozoa (
54,
69). There are limited studies of the
molecular and cell biology of
Blastocystis. Despite accumulating
evidence indicating that the parasite is pathogenic and that
proteases are involved in pathogenesis, not a single virulence
factor gene has been identified, cloned, and characterized.
As more studies are conducted, the roles of each
Blastocystis subtype in disease will become clearer. Greater collaboration
among research groups is needed. A key research priority is
to elucidate the pathogenic potential of the parasite and to
understand its pathogenesis. Once these are clarified, there
will be a surge in interest in other relevant aspects of
Blastocystis biology, including diagnosis and treatment.

ACKNOWLEDGMENTS
I am especially grateful to Ng Geok Choo, N. P. Ramachandran,
Eileen Chen, and Manoj Kumar for research input and laboratory
support pertaining to our work mentioned in this review and
Sylvie Alonso, Cynthia He, Georges Snounou, and Mark Taylor
for helpful discussions and comments on various sections of
this review.
Research from K. S. W. Tan's laboratory has been supported by generous grants from the Academic Research Fund, National Medical Research Council, and Biomedical Research Council.

FOOTNOTES
* Mailing address: Laboratory of Molecular and Cellular Parasitology, Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore, 5 Science Drive 2, Singapore 117597, Republic of Singapore. Phone: (65) 6516 6780. Fax: (65) 6776 6872. E-mail:
mictank{at}nus.edu.sg 

REFERENCES
1 - Abe, N. 2004. Molecular and phylogenetic analysis of Blastocystis isolates from various hosts. Vet. Parasitol. 120:235-242.[CrossRef][Medline]
2 - Abe, N., Z. Wu, and H. Yoshikawa. 2003. Molecular characterization of Blastocystis isolates from birds by PCR with diagnostic primers and restriction fragment length polymorphism analysis of the small subunit ribosomal RNA gene. Parasitol. Res. 89:393-396.[CrossRef][Medline]
3 - Abe, N., Z. Wu, and H. Yoshikawa. 2003. Molecular characterization of Blastocystis isolates from primates. Vet. Parasitol. 113:321-325.[CrossRef][Medline]
4 - Abe, N., Z. Wu, and H. Yoshikawa. 2003. Zoonotic genotypes of Blastocystis hominis detected in cattle and pigs by PCR with diagnostic primers and restriction fragment length polymorphism analysis of the small subunit ribosomal RNA gene. Parasitol. Res. 90:124-128.[Medline]
5 - Abou El Naga, I. F., and A. Y. Negm. 2001. Morphology, histochemistry and infectivity of Blastocystis hominis cyst. J. Egypt. Soc. Parasitol. 31:627-635.[Medline]
6 - Aguiar, J. I., A. Q. Goncalves, F. C. Sodre, R. Pereira Sdos, M. N. Boia, E. R. de Lemos, and R. R. Daher. 2007. Intestinal protozoa and helminths among Terena Indians in the State of Mato Grosso do Sul: high prevalence of Blastocystis hominis. Rev. Soc. Bras. Med. Trop. 40:631-634.[Medline]
7 - Akdemir, C., and R. Helvaci. 2007. Evaluation of parasitology laboratory results of a group of people older than 15 years of age in Kutahya. Turkiye Parazitol. Derg. 31:129-132. (In Turkish.)[Medline]
8 - Aksoy, U., C. Akisu, S. Bayram-Delibas, S. Ozkoc, S. Sahin, and S. Usluca. 2007. Demographic status and prevalence of intestinal parasitic infections in schoolchildren in Izmir, Turkey. Turk. J. Pediatr. 49:278-282.[Medline]
9 - Al, F. D., and M. Hokelek. 2007. Is Blastocystis hominis an opportunist agent? Turkiye Parazitol. Derg. 31:28-36. (In Turkish.)[Medline]
10 - Al-Binali, A. M., C. S. Bello, K. El-Shewy, and S. E. Abdulla. 2006. The prevalence of parasites in commonly used leafy vegetables in South Western, Saudi Arabia. Saudi Med. J. 27:613-616.[Medline]
11 - Albrecht, H., H. J. Stellbrink, K. Koperski, and H. Greten. 1995. Blastocystis hominis in human immunodeficiency virus-related diarrhea. Scand. J. Gastroenterol. 30:909-914.[CrossRef][Medline]
12 - Alexeieff, A. 1911. Sur la nature des formations dites kystes de Trichomonas intestinalis. C. R. Soc. Biol. 71:296-298.
13 - al-Tawil, Y. S., M. A. Gilger, G. S. Gopalakrishna, C. Langston, and K. E. Bommer. 1994. Invasive Blastocystis hominis infection in a child. Arch. Pediatr. Adolesc. Med. 148:882-885.[Abstract/Free Full Text]
14 - Amin, A. M. 1997. Blastocystis hominis among apparently healthy food handlers in Jeddah, Saudi Arabia. J. Egypt. Soc. Parasitol. 27:817-823.[Medline]
15 - Amin, O. M. 2002. Seasonal prevalence of intestinal parasites in the United States during 2000. Am. J. Trop. Med. Hyg. 66:799-803.[Abstract]
16 - Andiran, N., Z. C. Acikgoz, S. Turkay, and F. Andiran. 2006. Blastocystis hominis—an emerging and imitating cause of acute abdomen in children. J. Pediatr. Surg. 41:1489-1491.[CrossRef][Medline]
17 - Arisue, N., T. Hashimoto, and H. Yoshikawa. 2003. Sequence heterogeneity of the small subunit ribosomal RNA genes among Blastocystis isolates. Parasitology 126:1-9.[CrossRef][Medline]
18 - Arisue, N., T. Hashimoto, H. Yoshikawa, Y. Nakamura, G. Nakamura, F. Nakamura, T. A. Yano, and M. Hasegawa. 2002. Phylogenetic position of Blastocystis hominis and of stramenopiles inferred from multiple molecular sequence data. J. Eukaryot. Microbiol. 49:42-53.[CrossRef][Medline]
19 - Armentia, A., J. Mendez, A. Gomez, E. Sanchis, A. Fernandez, R. de la Fuente, and P. Sanchez. 1993. Urticaria by Blastocystis hominis. Successful treatment with paromomycin. Allergol. Immunopathol. (Madrid) 21:149-151.
20 - Babb, R. R., and S. Wagener. 1989. Blastocystis hominis—a potential intestinal pathogen. West. J. Med. 151:518-519.[Medline]
21 - Baldo, E. T., V. Y. Belizario, W. U. De Leon, H. H. Kong, and D. I. Chung. 2004. Infection status of intestinal parasites in children living in residential institutions in Metro Manila, the Philippines. Korean J. Parasitol. 42:67-70.[Medline]
22 - Barahona Rondon, L., C. Maguina Vargas, C. Naquira Velarde, I. A. Terashima, and R. Tello. 2003. Human blastocystosis: prospective study symptomatology and associated epidemiological factors. Rev. Gastroenterol. Peru 23:29-35. (In Spanish.)[Medline]
23 - Bartlett, J. G. 1997. Clostridium difficile infection: pathophysiology and diagnosis. Semin. Gastrointest. Dis. 8:12-21.[Medline]
24 - Basualdo, J., B. Pezzani, M. De Luca, A. Cordoba, and M. Apezteguia. 2000. Screening of the municipal water system of La Plata, Argentina, for human intestinal parasites. Int. J. Hyg. Environ. Health 203:177-182.[CrossRef][Medline]
25 - Basualdo, J. A., M. A. Cordoba, M. M. de Luca, M. L. Ciarmela, B. C. Pezzani, M. S. Grenovero, and M. C. Minvielle. 2007. Intestinal parasitoses and environmental factors in a rural population of Argentina, 2002-2003. Rev. Inst. Med. Trop. Sao Paulo 49:251-255.[Medline]
26 - Bercu, T. E., W. A. Petri, and J. W. Behm. 2007. Amebic colitis: new insights into pathogenesis and treatment. Curr. Gastroenterol. Rep. 9:429-433.[CrossRef][Medline]
27 - Berkes, J., V. K. Viswanathan, S. D. Savkovic, and G. Hecht. 2003. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 52:439-451.[Abstract/Free Full Text]
28 - Biedermann, T., K. Hartmann, A. Sing, and B. Przybilla. 2002. Hypersensitivity to non-steroidal anti-inflammatory drugs and chronic urticaria cured by treatment of Blastocystis hominis infection. Br. J. Dermatol. 146:1113-1114.[CrossRef][Medline]
29 - Birky, C. W., Jr. 1996. Heterozygosity, heteromorphy, and phylogenetic trees in asexual eukaryotes. Genetics 144:427-437.[Abstract]
30 - Boeck, W. C., and J. Drbohlav. 1925. The cultivation of Entamoeba histolytica. Am. J. Hyg. 5:371-407.
31 - Böhm-Gloning, B., J. Knobloch, and B. Walderich. 1997. Five subgroups of Blastocystis hominis from symptomatic and asymptomatic patients revealed by restriction site analysis of PCR-amplified 16S-like rDNA. Trop. Med. Int. Health 2:771-778.[CrossRef][Medline]
32 - Borda, C. E., M. J. Rea, J. R. Rosa, and C. Maidana. 1996. Intestinal parasitism in San Cayetano, Corrientes, Argentina. Bull. Pan. Am. Health Organ. 30:227-233.[Medline]
33 - Boreham, P. F., and D. J. Stenzel. 1993. Blastocystis in humans and animals: morphology, biology, and epizootiology. Adv. Parasitol. 32:1-70.[Medline]
34 - Brandonisio, O., P. Maggi, M. A. Panaro, S. Lisi, A. Andriola, A. Acquafredda, and G. Angarano. 1999. Intestinal protozoa in HIV-infected patients in Apulia, South Italy. Epidemiol. Infect. 123:457-462.[CrossRef][Medline]
35 - Bratt, D. E., and E. S. Tikasingh. 1990. Blastocystis hominis in two children of one family. West Indian Med. J. 39:57-58.[Medline]
36 - Brites, C., M. G. Barberino, M. A. Bastos, M. Sampaio Sa, and N. Silva. 1997. Blastocystis hominis as a potential cause of diarrhea in AIDS patients: a report of six cases in Bahia, Brazil. Braz. J. Infect. Dis. 1:91-94.[Medline]
37 - Brumpt, E. 1912. Blastocystis hominis n sp. et formes voisines. Bull. Soc. Pathol. Exot. 5:725-730.
38 - Carbajal, J. A., L. del Castillo, M. D. Lanuza, J. Villar, and R. Borrás. 1997. Karyotypic diversity among Blastocystis hominis isolates. Int. J. Parasitol. 27:941-945.[CrossRef][Medline]
39 - Cassano, N., B. M. Scoppio, M. C. Loviglio, and G. A. Vena. 2005. Remission of delayed pressure urticaria after eradication of Blastocystis hominis. Acta Derm. Venereol. 85:357-358.[Medline]
40 - Cassidy, M. F., D. J. Stenzel, and P. F. Boreham. 1994. Electron microscopy of surface structures of Blastocystis sp. from different hosts. Parasitol. Res. 80:505-511.[CrossRef][Medline]
41 - Cavalier-Smith, T. 1998. A revised six-kingdom system of life. Biol. Rev. Camb. Philos. Soc. 73:203-266.[Medline]
42 - Cavalier-Smith, T. 1997. Sagenista and Bigyra, two phyla of heterotrophic heterokont chromists. Archiv. Protist. 148:253-267.
43 - Chen, T. L., C. C. Chan, H. P. Chen, C. P. Fung, C. P. Lin, W. L. Chan, and C. Y. Liu. 2003. Clinical characteristics and endoscopic findings associated with Blastocystis hominis in healthy adults. Am. J. Trop. Med. Hyg. 69:213-216.[Abstract/Free Full Text]
44 - Chen, X. Q., M. Singh, L. C. Ho, K. T. Moe, S. W. Tan, and E. H. Yap. 1997. A survey of Blastocystis sp. in rodents. Lab. Anim. Sci. 47:91-94.[Medline]
45 - Chen, X. Q., M. Singh, L. C. Ho, S. W. Tan, G. C. Ng, K. T. Moe, and E. H. Yap. 1997. Description of a Blastocystis species from Rattus norvegicus. Parasitol. Res. 83:313-318.[CrossRef][Medline]
46 - Chen, X. Q., M. Singh, J. Howe, L. C. Ho, S. W. Tan, and E. H. Yap. 1999. In vitro encystation and excystation of Blastocystis ratti. Parasitology 118:151-160.[CrossRef][Medline]
47 - Cheng, H. S., Y. L. Guo, and J. W. Shin. 2003. Hematological effects of Blastocystis hominis infection in male foreign workers in Taiwan. Parasitol. Res. 90:48-51.[Medline]
48 - Cheng, H. S., Z. F. Haung, W. H. Lan, T. C. Kuo, and J. W. Shin. 2006. Epidemiology of Blastocystis hominis and other intestinal parasites in a Vietnamese female immigrant population in southern Taiwan. Kaohsiung J. Med. Sci. 22:166-170.[Medline]
49 - Chunge, R. N., N. Nagelkerke, P. N. Karumba, N. Kaleli, M. Wamwea, N. Mutiso, E. O. Andala, J. Gachoya, R. Kiarie, and S. N. Kinoti. 1991. Longitudinal study of young children in Kenya: intestinal parasitic infection with special reference to Giardia lamblia, its prevalence, incidence and duration, and its association with diarrhoea and with other parasites. Acta Trop. 50:39-49.[CrossRef][Medline]
50 - Cimerman, S., M. C. Ladeira, and W. A. Iuliano. 2003. Blastocystosis: nitazoxanide as a new therapeutic option. Rev. Soc. Bras. Med. Trop. 36:415-417. (In Portugese.)[Medline]
51 - Cirioni, O., A. Giacometti, D. Drenaggi, F. Ancarani, and G. Scalise. 1999. Prevalence and clinical relevance of Blastocystis hominis in diverse patient cohorts. Eur. J. Epidemiol. 15:389-393.[Medline]
52 - Clark, C. G. 2000. Cryptic genetic variation in parasitic protozoa. J. Med. Microbiol. 49:489-491.[Medline]
53 - Clark, C. G. 1997. Extensive genetic diversity in Blastocystis hominis. Mol. Biochem. Parasitol. 87:79-83.[CrossRef][Medline]
54 - Coppel, R. L., and C. G. Black. 2005. Parasite genomes. Int. J. Parasitol. 35:465-479.[CrossRef][Medline]
55 - Cruz Licea, V., A. Plancarte Crespo, C. Moran Alvarez, S. Valencia Rojas, G. Rodriguez Sasnchez, and L. Vega Franco. 2003. Blastocystis hominis among food vendors in Xochimilco markets. Rev. Latinoam. Microbiol. 45:12-15.[Medline]
56 - Culha, G. 2006. The distribution of patients with intestinal parasites presenting at the Parasitology Laboratory of the Mustafa Kemal University Medical Faculty. Turkiye Parazitol. Derg. 30:302-304. (In Turkish.)[Medline]
57 - Danchaivijitr, S., Y. Rongrungruang, U. Kachintorn, V. Techasathit, S. Pakaworavuthi, and K. Kachintorn. 2005. Prevalence and effectiveness of an education program on intestinal pathogens in food handlers. J. Med. Assoc. Thai. 88(Suppl. 10):S31-S35.
58 - Denney, C. F., L. Eckmann, and S. L. Reed. 1999. Chemokine secretion of human cells in response to Toxoplasma gondii infection. Infect. Immun. 67:1547-1552.[Abstract/Free Full Text]
59 - Devera, R. A., V. J. Velasquez, and M. J. Vasquez. 1998. Blastocystosis in preschool children from Bolivar City, Venezuela. Cad. Saude Publica 14:401-407. (In Spanish.)[Medline]
60 - Diaczok, B. J., and J. Rival. 1987. Diarrhea due to Blastocystis hominis: an old organism revisited. South. Med. J. 80:931-932.[CrossRef][Medline]
61 - Diaz, E., J. Mondragon, E. Ramirez, and R. Bernal. 2003. Epidemiology and control of intestinal parasites with nitazoxanide in children in Mexico. Am. J. Trop. Med. Hyg. 68:384-385.[Abstract/Free Full Text]
62 - Dogruman-Al, F., H. Dagci, H. Yoshikawa, O. Kurt, and M. Demirel. 2008. A possible link between subtype 2 and asymptomatic infections of Blastocystis hominis. Parasitol. Res. 103:685-689.[CrossRef][Medline]
63 - Doyle, P. W., M. M. Helgason, R. G. Mathias, and E. M. Proctor. 1990. Epidemiology and pathogenicity of Blastocystis hominis. J. Clin. Microbiol. 28:116-121.[Abstract/Free Full Text]
64 - Duda, A., D. J. Stenzel, and P. F. Boreham. 1998. Detection of Blastocystis sp. in domestic dogs and cats. Vet. Parasitol. 76:9-17.[CrossRef][Medline]
65 - Dunn, L. A., P. F. Boreham, and D. J. Stenzel. 1989. Ultrastructural variation of Blastocystis hominis stocks in culture. Int. J. Parasitol. 19:43-56.[CrossRef][Medline]
66 - Eckmann, L. 2003. Mucosal defences against Giardia. Parasite Immunol. 25:259-270.[CrossRef][Medline]
67 - El-Shazly, A. M., A. A. Abdel-Magied, S. N. El-Beshbishi, H. A. El-Nahas, M. A. Fouad, and M. S. Monib. 2005. Blastocystis hominis among symptomatic and asymptomatic individuals in Talkha Center, Dakahlia Governorate, Egypt. J. Egypt. Soc. Parasitol. 35:653-666.[Medline]
68 - Elshazly, A. M., H. M. Elsheikha, D. M. Soltan, K. A. Mohammad, and T. A. Morsy. 2007. Protozoal pollution of surface water sources in Dakahlia Governorate, Egypt. J. Egypt. Soc. Parasitol. 37:51-64.[Medline]
69 - Ersfeld, K. 2003. Genomes and genome projects of protozoan parasites. Curr. Issues Mol. Biol. 5:61-74.[Medline]
70 - Escobedo, A. A., R. Canete, and F. A. Nunez. 2007. Intestinal protozoan and helminth infections in the Municipality San Juan y Martinez, Pinar del Rio, Cuba. Trop. Doct. 37:236-238.[Abstract/Free Full Text]
71 - Estevez, E. G., and J. A. Levine. 1985. Examination of preserved stool specimens for parasites: lack of value of the direct wet mount. J. Clin. Microbiol. 22:666-667.[Abstract/Free Full Text]
72 - Florez, A. C., D. A. Garcia, L. Moncada, and M. Beltran. 2003. Prevalence of microsporidia and other intestinal parasites in patients with HIV infection, Bogota, 2001. Biomedica 23:274-282. (In Spanish.)[Medline]
73 - Fotedar, R., D. Stark, N. Beebe, D. Marriott, J. Ellis, and J. Harkness. 2007. Laboratory diagnostic techniques for Entamoeba species. Clin. Microbiol. Rev. 20:511-532.[Abstract/Free Full Text]
74 - Frost, F. J., E. Fea, G. Gilli, F. Biorci, T. M. Muller, G. F. Craun, and R. L. Calderon. 2000. Serological evidence of Cryptosporidium infections in southern Europe. Eur. J. Epidemiol. 16:385-390.[CrossRef][Medline]
75 - Garavelli, P. L. 1991. The therapy of blastocystosis. J. Chemother. 3(Suppl. 1):245-246.[Medline]
76 - Garavelli, P. L., L. Scaglione, A. Merighi, and M. Libanore. 1992. Endoscopy of blastocystosis (Zierdt-Garavelli disease). Ital. J. Gastroenterol. 24:206.[Medline]
77 - Garcia, L. S. 2007. Diagnostic medical parasitology, 5th ed. ASM Press, Washington, DC.
78 - Gardner, B. B., D. J. Del Junco, J. Fenn, and J. H. Hengesbaugh. 1980. Comparison of direct wet mount and trichrome staining techniques for detecting Entamoeba species trophozoites in stools. J. Clin. Microbiol. 12:656-658.[Abstract/Free Full Text]
79 - Gassama, A., P. S. Sow, F. Fall, P. Camara, A. Gueye-N'diaye, R. Seng, B. Samb, S. M'Boup, and A. Aidara-Kane. 2001. Ordinary and opportunistic enteropathogens associated with diarrhea in Senegalese adults in relation to human immunodeficiency virus serostatus. Int. J. Infect. Dis. 5:192-198.[CrossRef][Medline]
80 - Giacometti, A., O. Cirioni, L. Antonicelli, G. D'Amato, C. Silvestri, M. S. Del Prete, and G. Scalise. 2003. Prevalence of intestinal parasites among individuals with allergic skin diseases. J. Parasitol. 89:490-492.[CrossRef][Medline]
81 - Giacometti, A., O. Cirioni, M. Balducci, D. Drenaggi, M. Quarta, M. De Federicis, P. Ruggeri, D. Colapinto, G. Ripani, and G. Scalise. 1997. Epidemiologic features of intestinal parasitic infections in Italian mental institutions. Eur. J. Epidemiol. 13:825-830.[CrossRef][Medline]
82 - Giacometti, A., O. Cirioni, A. Fiorentini, M. Fortuna, and G. Scalise. 1999. Irritable bowel syndrome in patients with Blastocystis hominis infection. Eur. J. Clin. Microbiol. Infect. Dis. 18:436-439.[CrossRef][Medline]
83 - Govind, S. K., A. A. Khairul, and H. V. Smith. 2002. Multiple reproductive processes in Blastocystis. Trends Parasitol. 18:528.[Medline]
84 - Grabensteiner, E., D. Liebhart, H. Weissenbock, and M. Hess. 2006. Broad dissemination of Histomonas meleagridis determined by the detection of nucleic acid in different organs after experimental infection of turkeys and specified pathogen-free chickens using a mono-eukaryotic culture of the parasite. Parasitol. Int. 55:317-322.[CrossRef][Medline]
85 - Graczyk, T. K., C. K. Shiff, L. Tamang, F. Munsaka, A. M. Beitin, and W. J. Moss. 2005. The association of Blastocystis hominis and Endolimax nana with diarrheal stools in Zambian school-age children. Parasitol. Res. 98:38-43.[CrossRef][Medline]
86 - Grossman, I., L. M. Weiss, D. Simon, H. B. Tanowitz, and M. Wittner. 1992. Blastocystis hominis in hospital employees. Am. J. Gastroenterol. 87:729-732.[Medline]
87 - Guglielmetti, P., C. Cellesi, N. Figura, and A. Rossolini. 1989. Family outbreak of Blastocystis hominis associated gastroenteritis. Lancet ii:1394.
88 - Guimarães, S., and M. I. Sogayar. 1993. Blastocystis hominis: occurrence in children and staff members of municipal day-care centers from Botucatu, Sao Paulo State, Brazil. Mem. Inst. Oswaldo Cruz 88:427-429.[Medline]
89 - Guirges, S. Y., and N. S. Al-Waili. 1987. Blastocystis hominis: evidence for human pathogenicity and effectiveness of metronidazole therapy. Clin. Exp. Pharmacol. Physiol. 14:333-335.[CrossRef][Medline]
90 - Gupta, R., and K. Parsi. 2006. Chronic urticaria due to Blastocystis hominis. Australas. J. Dermatol. 47:117-119.[CrossRef][Medline]
91 - Hailemariam, G., A. Kassu, G. Abebe, E. Abate, D. Damte, E. Mekonnen, and F. Ota. 2004. Intestinal parasitic infections in HIV/AIDS and HIV seronegative individuals in a teaching hospital, Ethiopia. Jpn. J. Infect. Dis. 57:41-43.[Medline]
92 - Haresh, K., K. Suresh, A. K. Anus, and S. Saminathan. 1999. Isolate resistance of Blastocystis hominis to metronidazole. Trop. Med. Int. Health 4:274-277.[CrossRef][Medline]
93 - Hasegawa, M., and T. Hashimoto. 1993. Ribosomal RNA trees misleading? Nature 361:23.[Medline]
94 - Herwaldt, B. L., K. R. de Arroyave, S. P. Wahlquist, A. M. de Merida, A. S. Lopez, and D. D. Juranek. 2001. Multiyear prospective study of intestinal parasitism in a cohort of Peace Corps volunteers in Guatemala. J. Clin. Microbiol. 39:34-42.[Abstract/Free Full Text]
95 - Hess, M., T. Kolbe, E. Grabensteiner, and H. Prosl. 2006. Clonal cultures of Histomonas meleagridis, Tetratrichomonas gallinarum and a Blastocystis sp. established through micromanipulation. Parasitology 133:547-554.[CrossRef][Medline]
96 - Hirata, T., H. Nakamura, N. Kinjo, A. Hokama, F. Kinjo, N. Yamane, and J. Fujita. 2007. Prevalence of Blastocystis hominis and Strongyloides stercoralis infection in Okinawa, Japan. Parasitol. Res. 101:1717-1719.[CrossRef][Medline]
97 - Ho, L. C., A. Armiugam, K. Jeyaseelan, E. H. Yap, and M. Singh. 2000. Blastocystis elongation factor-1alpha: genomic organization, taxonomy and phylogenetic relationships. Parasitology 121:135-144.[CrossRef][Medline]
98 - Ho, L. C., M. Singh, G. Suresh, G. C. Ng, and E. H. Yap. 1993. Axenic culture of Blastocystis hominis in Iscove's modified Dulbecco's medium. Parasitol. Res. 79:614-616.[CrossRef][Medline]
99 - Ho, L. C., M. Singh, K. Suresh, G. C. Ng, and E. H. Yap. 1994. A study of the karyotypic patterns of Blastocystis hominis by pulsed-field gradient electrophoresis. Parasitol. Res. 80:620-622.[CrossRef][Medline]
100 - Hoevers, J. D., and K. F. Snowden. 2005. Analysis of the ITS region and partial ssu and lsu rRNA genes of Blastocystis and Proteromonas lacertae. Parasitology 131:187-196.[CrossRef][Medline]
101 - Horiki, N., M. Maruyama, Y. Fujita, T. Yonekura, S. Minato, and Y. Kaneda. 1997. Epidemiologic survey of Blastocystis hominis infection in Japan. Am. J. Trop. Med. Hyg. 56:370-374.[Abstract/Free Full Text]
102 - Hu, K. C., C. C. Lin, T. E. Wang, C. Y. Liu, M. J. Chen, and W. H. Chang. 2008. Amoebic liver abscess or is it? Gut 57:627, 683.[Free Full Text]
103 - Huang, D. B., and A. C. White. 2006. An updated review on Cryptosporidium and Giardia. Gastroenterol. Clin. N. Am. 35:291-314.[CrossRef][Medline]
104 - Hussain, R., W. Jaferi, S. Zuberi, R. Baqai, N. Abrar, A. Ahmed, and V. Zaman. 1997. Significantly increased IgG2 subclass antibody levels to Blastocystis hominis in patients with irritable bowel syndrome. Am. J. Trop. Med. Hyg. 56:301-306.[Abstract/Free Full Text]
105 - Hussein, E. M., A. M. Hussein, M. M. Eida, and M. M. Atwa. 2008. Pathophysiological variability of different genotypes of human Blastocystis hominis Egyptian isolates in experimentally infected rats. Parasitol. Res. 102:853-860.[CrossRef][Medline]
106 - Iguchi, A., A. Ebisu, S. Nagata, Y. Saitou, H. Yoshikawa, S. Iwatani, and I. Kimata. 2007. Infectivity of different genotypes of human Blastocystis hominis isolates in chickens and rats. Parasitol. Int. 56:107-112.[CrossRef][Medline]
107 - Jelinek, T., G. Peyerl, T. Löscher, F. von Sonnenburg, and H. D. Nothdurft. 1997. The role of Blastocystis hominis as a possible intestinal pathogen in travellers. J. Infect. 35:63-66.[CrossRef][Medline]
108 - Johnson, A. M., A. Thanou, P. F. Boreham, and P. R. Baverstock. 1989. Blastocystis hominis: phylogenetic affinities determined by rRNA sequence comparison. Exp. Parasitol. 68:283-288.[CrossRef][Medline]
109 - Jones, M. S., II, R. D. Ganac, G. Hiser, N. R. Hudson, A. Le, and C. M. Whipps. 2008. Detection of Blastocystis from stool samples using real-time PCR. Parasitol. Res. 103:551-557.[CrossRef][Medline]
110 - Jones, W. R. 1946. The experimental infection of rats with Entamoeba histolytica. Ann. Trop. Med. Parasitol. 40:130.
111 - Kain, K. C., M. A. Noble, H. J. Freeman, and R. L. Barteluk. 1987. Epidemiology and clinical features associated with Blastocystis hominis infection. Diagn. Microbiol. Infect. Dis. 8:235-244.[CrossRef][Medline]
112 - Kaneda, Y., N. Horiki, X. Cheng, H. Tachibana, and Y. Tsutsumi. 2000. Serologic response to Blastocystis hominis infection in asymptomatic individuals. Tokai J. Exp. Clin. Med. 25:51-56.[Medline]
113 - Kaneda, Y., N. Horiki, X. J. Cheng, Y. Fujita, M. Maruyama, and H. Tachibana. 2001. Ribodemes of Blastocystis hominis isolated in Japan. Am. J. Trop. Med. Hyg. 65:393-396.[Abstract]
114 - Karanis, P., C. Kourenti, and H. Smith. 2007. Waterborne transmission of protozoan parasites: a worldwide review of outbreaks and lessons learnt. J. Water Health 5:1-38.[CrossRef][Medline]
115 - Katsarou-Katsari, A., C. M. Vassalos, K. Tzanetou, G. Spanakos, C. Papadopoulou, and N. Vakalis. 2008. Acute urticaria associated with amoeboid forms of Blastocystis sp. subtype 3. Acta Derm. Venereol. 88:80-81.[CrossRef][Medline]
116 - Kaya, S., E. S. Cetin, B. C. Aridogan, S. Arikan, and M. Demirci. 2007. Pathogenicity of Blastocystis hominis, a clinical reevaluation. Turkiye Parazitol. Derg. 31:184-187.[Medline]
117 - Kellogg, J. A., and C. J. Elder. 1999. Justification for use of a single trichrome stain as the sole means for routine detection of intestinal parasites in concentrated stool specimens. J. Clin. Microbiol. 37:835-837.[Abstract/Free Full Text]
118 - Khalifa, A. M., M. M. El Temsahy, and I. F. Abou El Naga. 2001. Effect of ozone on the viability of some protozoa in drinking water. J. Egypt. Soc. Parasitol. 31:603-616.[Medline]
119 - Khan, Z. A., and I. S. Alkhalife. 2005. Prevalence of Blastocystis hominis among "healthy" food handlers in Dammam, Saudi Arabia. J. Egypt. Soc. Parasitol. 35:395-401.[Medline]
120 - Kick, G., F. Rueff, and B. Przybilla. 2002. Palmoplantar pruritus subsiding after Blastocystis hominis eradication. Acta Derm. Venereol. 82:60.[CrossRef][Medline]
121 - Knobloch, J., and E. Mannweiler. 1983. Development and persistence of antibodies to Entamoeba histolytica in patients with amebic liver abscess. Analysis of 216 cases. Am. J. Trop. Med. Hyg. 32:727-732.[Abstract/Free Full Text]
122 - König, G., and H. E. Müller. 1997. Blastocystis hominis in animals: incidence of four serogroups. Zentralbl. Bakteriol. 286:435-440.[Medline]
123 - Koutsavlis, A. T., L. Valiquette, R. Allard, and J. Soto. 2001. Blastocystis hominis: a new pathogen in day-care centres? Can. Commun. Dis. Rep. 27:76-84.[Medline]
124 - Krech, T., X. M. Nguyen, and H. Spicher. 1990. Blastocystis hominis in feces. An assessment of 56 cases. Schweiz. Med. Wochenschr. 120:742-744. (In German.)[Medline]
125 - Kuhls, T. L., D. A. Mosier, D. L. Crawford, and J. Griffis. 1994. Seroprevalence of cryptosporidial antibodies during infancy, childhood, and adolescence. Clin. Infect. Dis. 18:731-735.[Medline]
126 - Kukoschke, K. G., and H. E. Müller. 1991. SDS-PAGE and immunological analysis of different axenic Blastocystis hominis strains. J. Med. Microbiol. 35:35-39.[Abstract/Free Full Text]
127 - Lanuza, M. D., J. A. Carbajal, and R. Borrás. 1996. Identification of surface coat carbohydrates in Blastocystis hominis by lectin probes. Int. J. Parasitol. 26:527-532.[CrossRef][Medline]
128 - Lanuza, M. D., J. A. Carbajal, J. Villar, and R. Borrás. 1997. Description of an improved method for Blastocystis hominis culture and axenization. Parasitol. Res. 83:60-63.[CrossRef][Medline]
129 - Laurent, F., L. Eckmann, T. C. Savidge, G. Morgan, C. Theodos, M. Naciri, and M. F. Kagnoff. 1997. Cryptosporidium parvum infection of human intestinal epithelial cells induces the polarized secretion of C-X-C chemokines. Infect. Immun. 65:5067-5073.[Abstract/Free Full Text]
130 - Lavier, G. 1952. Blastocystis spp. Ann. Parasitol. Hum. Comp. 27:339-356. (In French.)[Medline]
131 - Leder, K., M. E. Hellard, M. I. Sinclair, C. K. Fairley, and R. Wolfe. 2005. No correlation between clinical symptoms and Blastocystis hominis in immunocompetent individuals. J. Gastroenterol. Hepatol. 20:1390-1394.[CrossRef][Medline]
132 - Lee, M. G., and D. J. Stenzel. 1999. A survey of Blastocystis in domestic chickens. Parasitol. Res. 85:109-117.[CrossRef][Medline]
133 - Lee, M. J. 1991. Pathogenicity of Blastocystis hominis. J. Clin. Microbiol. 29:2089.[Free Full Text]
134 - Leelayoova, S., R. Rangsin, P. Taamasri, T. Naaglor, U. Thathaisong, and M. Mungthin. 2004. Evidence of waterborne transmission of Blastocystis hominis. Am. J. Trop. Med. Hyg. 70:658-662.[Abstract/Free Full Text]
135 - Leelayoova, S., P. Taamasri, R. Rangsin, T. Naaglor, U. Thathaisong, and M. Mungthin. 2002. In-vitro cultivation: a sensitive method for detecting Blastocystis hominis. Ann. Trop. Med. Parasitol. 96:803-807.[CrossRef][Medline]
136 - Levy, Y., J. George, and Y. Shoenfeld. 1996. Severe Blastocystis hominis in an elderly man. J. Infect. 33:57-59.[CrossRef][Medline]
137 - Li, L. H., X. P. Zhang, S. Lv, L. Zhang, H. Yoshikawa, Z. Wu, P. Steinmann, J. Utzinger, X. M. Tong, S. H. Chen, and X. N. Zhou. 2007. Cross-sectional surveys and subtype classification of human Blastocystis isolates from four epidemiological settings in China. Parasitol. Res. 102:83-90.[CrossRef][Medline]
138 - Li, L. H., X. N. Zhou, Z. W. Du, X. Z. Wang, L. B. Wang, J. Y. Jiang, H. Yoshikawa, P. Steinmann, J. Utzinger, Z. Wu, J. X. Chen, S. H. Chen, and L. Zhang. 2007. Molecular epidemiology of human Blastocystis in a village in Yunnan province, China. Parasitol. Int. 56:281-286.[CrossRef][Medline]
139 - Long, H. Y., A. Handschack, W. König, and A. Ambrosch. 2001. Blastocystis hominis modulates immune responses and cytokine release in colonic epithelial cells. Parasitol. Res. 87:1029-1030.[Medline]
140 - Lucia, J. F., C. Aguilar, and A. Betran. 2007. Blastocystis hominis colitis in a haemophilic patient as a cause of lower gastrointestinal bleeding. Haemophilia 13:224-225.[CrossRef][Medline]
141 - Luster, M. I., G. A. Leslie, and R. K. Cole. 1976. Selective IgA deficiency in chickens with spontaneous autoimmune thyroiditis. Nature 263:331.[CrossRef][Medline]
142 - MacPherson, D. W., and W. M. MacQueen. 1994. Morphological diversity of Blastocystis hominis in sodium acetate-acetic acid-formalin-preserved stool samples stained with iron hematoxylin. J. Clin. Microbiol. 32:267-268.[Abstract/Free Full Text]
143 - Mahmoud, M. S., and W. A. Saleh. 2003. Secretory and humoral antibody responses to Blastocystis hominis in symptomatic and asymptomatic human infections. J. Egypt. Soc. Parasitol. 33:13-30.[Medline]
144 - Markell, E. K., and M. P. Udkow. 1986. Blastocystis hominis: pathogen or fellow traveler? Am. J. Trop. Med. Hyg. 35:1023-1026.[Abstract/Free Full Text]
145 - Martin-Sanchez, A. M., A. Canut-Blasco, J. Rodriguez-Hernandez, I. Montes-Martinez, and J. A. Garcia-Rodriguez. 1992. Epidemiology and clinical significance of Blastocystis hominis in different population groups in Salamanca (Spain). Eur. J. Epidemiol. 8:553-559.[CrossRef][Medline]
146 - Matsumoto, Y., M. Yamada, and Y. Yoshida. 1987. Light-microscopical appearance and ultrastructure of Blastocystis hominis, an intestinal parasite of man. Zentralbl. Bakteriol. Mikrobiol. Hyg. A 264:379-385.[Medline]
147 - Menounos, P. G., G. Spanakos, N. Tegos, C. M. Vassalos, C. Papadopoulou, and N. C. Vakalis. 2008. Direct detection of Blastocystis sp. in human faecal samples and subtype assignment using single strand conformational polymorphism and sequencing. Mol. Cell. Probes 22:24-29.[CrossRef][Medline]
148 - Micheloud, D., J. Jensen, E. Fernandez-Cruz, and J. Carbone. 2007. Chronic angioedema and Blastocystis hominis infection. Rev. Gastroenterol. Peru 27:191-193. (In Spanish.)[Medline]
149 - Miller, S. A., C. L. Rosario, E. Rojas, and J. V. Scorza. 2003. Intestinal parasitic infection and associated symptoms in children attending day care centres in Trujillo, Venezuela. Trop. Med. Int. Health 8:342-347.[CrossRef][Medline]
150 - Minvielle, M. C., B. C. Pezzani, M. A. Cordoba, M. M. De Luca, M. C. Apezteguia, and J. A. Basualdo. 2004. Epidemiological survey of Giardia spp. and Blastocystis hominis in an Argentinian rural community. Korean J. Parasitol. 42:121-127.[Medline]
151 - Moe, K. T., M. Singh, P. Gopalakrishnakone, L. C. Ho, S. W. Tan, X. Q. Chen, and E. H. Yap. 1998. Cytopathic effect of Blastocystis hominis after intramuscular inoculation into laboratory mice. Parasitol. Res. 84:450-454.[CrossRef][Medline]
152 - Moe, K. T., M. Singh, J. Howe, L. C. Ho, S. W. Tan, X. Q. Chen, G. C. Ng, and E. H. Yap. 1997. Experimental Blastocystis hominis infection in laboratory mice. Parasitol. Res. 83:319-325.[CrossRef][Medline]
153 - Moe, K. T., M. Singh, J. Howe, L. C. Ho, S. W. Tan, X. Q. Chen, and E. H. Yap. 1999. Development of Blastocystis hominis cysts into vacuolar forms in vitro. Parasitol. Res. 85:103-108.[CrossRef][Medline]
154 - Moe, K. T., M. Singh, J. Howe, L. C. Ho, S. W. Tan, G. C. Ng, X. Q. Chen, and E. H. Yap. 1996. Observations on the ultrastructure and viability of the cystic stage of Blastocystis hominis from human feces. Parasitol. Res. 82:439-444.[CrossRef][Medline]
155 - Moghaddam, D. D., E. Ghadirian, and M. Azami. 2005. Blastocystis hominis and the evaluation of efficacy of metronidazole and trimethoprim/sulfamethoxazole. Parasitol. Res. 96:273-275.[CrossRef][Medline]
156 - Müller, H. E. 1994. Four serologically different groups within the species Blastocystis hominis. Zentralbl. Bakteriol. 280:403-408.[Medline]
157 - Nagler, J., M. Brown, and R. Soave. 1993. Blastocystis hominis in inflammatory bowel disease. J. Clin. Gastroenterol. 16:109-112.[Medline]
158 - Nakamura, Y., T. Hashimoto, H. Yoshikawa, T. Kamaishi, F. Nakamura, K. Okamoto, and M. Hasegawa. 1996. Phylogenetic position of Blastocystis hominis that contains cytochrome-free mitochondria, inferred from the protein phylogeny of elongation factor 1 alpha. Mol. Biochem. Parasitol. 77:241-245.[CrossRef][Medline]
159 - Nasirudeen, A. M., Y. E. Hian, M. Singh, and K. S. Tan. 2004. Metronidazole induces programmed cell death in the protozoan parasite Blastocystis hominis. Microbiology 150:33-43.[Abstract/Free Full Text]
160 - Nasirudeen, A. M., K. S. Tan, M. Singh, and E. H. Yap. 2001. Programmed cell death in a human intestinal parasite, Blastocystis hominis. Parasitology 123:235-246.[Medline]
161 - Nassir, E., J. Awad, A. B. Abel, J. Khoury, M. Shay, and F. Lejbkowicz. 2004. Blastocystis hominis as a cause of hypoalbuminemia and anasarca. Eur. J. Clin. Microbiol. Infect. Dis. 23:399-402.[CrossRef][Medline]
162 - Navarrete, N., and P. Torres. 1994. Prevalence of infection by intestinal helminths and protozoa in school children from a coastal locality in the province of Valdivia, Chile. Bol. Chil. Parasitol. 49:79-80. (In Spanish.)[Medline]
163 - Navarro, C., M. V. Domínguez-Márquez, M. M. Garijo-Toledo, S. Vega-García, S. Fernández-Barredo, M. T. Pérez-Gracia, A. García, R. Borrás, and M. T. Gómez-Muñoz. 2008. High prevalence of Blastocystis sp. in pigs reared under intensive growing systems: frequency of ribotypes and associated risk factors. Vet. Parasitol. 153:347-358.[CrossRef][Medline]
164 - Ng, G. C., and K. S. Tan. 1999. Colony growth as a step towards axenization of Blastocystis isolates. Parasitol. Res. 85:678-679.[CrossRef][Medline]
165 - Nigro, L., L. Larocca, L. Massarelli, I. Patamia, S. Minniti, F. Palermo, and B. Cacopardo. 2003. A placebo-controlled treatment trial of Blastocystis hominis infection with metronidazole. J. Travel. Med. 10:128-130.[Medline]
166 - Nimri, L., and R. Batchoun. 1994. Intestinal colonization of symptomatic and asymptomatic schoolchildren with Blastocystis hominis. J. Clin. Microbiol. 32:2865-2866.[Abstract/Free Full Text]
167 - Nimri, L. F. 1993. Evidence of an epidemic of Blastocystis hominis infections in preschool children in northern Jordan. J. Clin. Microbiol. 31:2706-2708.[Abstract/Free Full Text]
168 - Nimri, L. F., and M. Meqdam. 2004. Enteropathogens associated with cases of gastroenteritis in a rural population in Jordan. Clin. Microbiol. Infect. 10:634-639.[CrossRef][Medline]
169 - Noël, C., F. Dufernez, D. Gerbod, V. P. Edgcomb, P. Delgado-Viscogliosi, L. C. Ho, M. Singh, R. Wintjens, M. L. Sogin, M. Capron, R. Pierce, L. Zenner, and E. Viscogliosi. 2005. Molecular phylogenies of Blastocystis isolates from different hosts: implications for genetic diversity, identification of species, and zoonosis. J. Clin. Microbiol. 43:348-355.[Abstract/Free Full Text]
170 - Noël, C., C. Peyronnet, D. Gerbod, V. P. Edgcomb, P. Delgado-Viscogliosi, M. L. Sogin, M. Capron, E. Viscogliosi, and L. Zenner. 2003. Phylogenetic analysis of Blastocystis isolates from different hosts based on the comparison of small-subunit rRNA gene sequences. Mol. Biochem. Parasitol. 126:119-123.[CrossRef][Medline]
171 - Noor Azian, M. Y., Y. M. San, C. C. Gan, M. Y. Yusri, Y. Nurulsyamzawaty, A. H. Zuhaizam, M. N. Maslawaty, I. Norparina, and I. Vythilingam. 2007. Prevalence of intestinal protozoa in an aborigine community in Pahang, Malaysia. Trop. Biomed. 24:55-62.[Medline]
172 - Nordlander, E., S. Phuphaisan, L. Bodhidatta, J. Arthur, and P. Echeverria. 1990. Microscopic examination of stools and a latex slide agglutination test for the rapid identification of bacterial enteric infections in Khmer children. Diagn. Microbiol. Infect. Dis. 13:273-276.[CrossRef][Medline]
173 - Noureldin, M. S., A. A. Shaltout, E. M. El Hamshary, and M. E. Ali. 1999. Opportunistic intestinal protozoal infections in immunocompromised children. J. Egypt. Soc. Parasitol. 29:951-961.[Medline]
174 - Odds, F. C., M. E. Bougnoux, D. J. Shaw, J. M. Bain, A. D. Davidson, D. Diogo, M. D. Jacobsen, M. Lecomte, S. Y. Li, A. Tavanti, M. C. Maiden, N. A. Gow, and C. d'Enfert. 2007. Molecular phylogenetics of Candida albicans. Eukaryot. Cell 6:1041-1052.[Abstract/Free Full Text]
175 - O'Gorman, M. A., S. R. Orenstein, R. Proujansky, R. M. Wadowsky, P. E. Putnam, and S. A. Kocoshis. 1993. Prevalence and characteristics of Blastocystis hominis infection in children. Clin. Pediatr. (Philadelphia) 32:91-96.[Abstract/Free Full Text]
176 - Ok, U. Z., M. Cirit, A. Uner, E. Ok, F. Akcicek, A. Basci, and M. A. Ozcel. 1997. Cryptosporidiosis and blastocystosis in renal transplant recipients. Nephron 75:171-174.[Medline]
177 - Ok, U. Z., N. Girginkardesler, C. Balcioglu, P. Ertan, T. Pirildar, and A. A. Kilimcioglu. 1999. Effect of trimethoprim-sulfamethaxazole in Blastocystis hominis infection. Am. J. Gastroenterol. 94:3245-3247.[CrossRef][Medline]
178 - Ortega, Y. R., and R. D. Adam. 1997. Giardia: overview and update. Clin. Infect. Dis. 25:545-549.[Medline]
179 - Özcakir, O., S. Güreser, S. Ergüven, Y. A. Yilmaz, R. Topalo
lu, and G. Hasçelik. 2007. Characteristics of Blastocystis hominis infection in a Turkish university hospital. Turkiye Parazitol. Derg. 31:277-282.[Medline] 180 - Özyurt, M., O. Kurt, K. Mølbak, H. V. Nielsen, T. Haznedaroglu, and C. R. Stensvold. 2008. Molecular epidemiology of Blastocystis infections in Turkey. Parasitol. Int. 57:300-306.[CrossRef][Medline]
181 - Pakandl, M. 1999. Blastocystis sp. from pigs: ultrastructural changes occurring during polyxenic cultivation in Iscove's modified Dulbecco's medium. Parasitol. Res. 85:743-748.[CrossRef][Medline]
182 - Pakandl, M. 1992. An experimental transmission of porcine strains of Blastocystis sp. in the laboratory mice and gerbils. Folia Parasitol. (Prague) 39:383-386.
183 - Parkar, U., R. J. Traub, S. Kumar, M. Mungthin, S. Vitali, S. Leelayoova, K. Morris, and R. C. Thompson. 2007. Direct characterization of Blastocystis from faeces by PCR and evidence of zoonotic potential. Parasitology 134:359-367.[CrossRef][Medline]
184 - Pasqui, A. L., E. Savini, M. Saletti, C. Guzzo, L. Puccetti, and A. Auteri. 2004. Chronic urticaria and Blastocystis hominis infection: a case report. Eur. Rev. Med. Pharmacol. Sci. 8:117-120.[Medline]
185 - Pegelow, K., R. Gross, K. Pietrzik, W. Lukito, A. L. Richards, and D. J. Fryauff. 1997. Parasitological and nutritional situation of school children in the Sukaraja district, West Java, Indonesia. Southeast Asian J. Trop. Med. Public Health 28:173-190.[Medline]
186 - Philippe, H., and J. Laurent. 1998. How good are deep phylogenetic trees? Curr. Opin. Genet. Dev. 8:616-623.[CrossRef][Medline]
187 - Phillips, B. P., and C. H. Zierdt. 1976. Blastocystis hominis: pathogenic potential in human patients and in gnotobiotes. Exp. Parasitol. 39:358-364.[CrossRef][Medline]
188 - Pikula, Z. P. 1987. Blastocystis hominis and human disease. J. Clin. Microbiol. 25:1581.[Free Full Text]
189 - Poxleitner, M. K., M. L. Carpenter, J. J. Mancuso, C. J. Wang, S. C. Dawson, and W. Z. Cande. 2008. Evidence for karyogamy and exchange of genetic material in the binucleate intestinal parasite Giardia intestinalis. Science 319:1530-1533.[Abstract/Free Full Text]
190 - Priest, J. W., C. Bern, J. M. Roberts, J. P. Kwon, A. G. Lescano, W. Checkley, L. Cabrera, D. M. Moss, M. J. Arrowood, C. R. Sterling, R. H. Gilman, and P. J. Lammie. 2005. Changes in serum immunoglobulin G levels as a marker for Cryptosporidium sp. infection in Peruvian children. J. Clin. Microbiol. 43:5298-5300.[Abstract/Free Full Text]
191 - Puthia, M. K., J. Lu, and K. S. Tan. 2008. Blastocystis ratti contains cysteine proteases that mediate interleukin-8 response from human intestinal epithelial cells in an NF-
B-dependent manner. Eukaryot. Cell 7:435-443.[Abstract/Free Full Text] 192 - Puthia, M. K., S. W. Sio, J. Lu, and K. S. Tan. 2006. Blastocystis ratti induces contact-independent apoptosis, F-actin rearrangement, and barrier function disruption in IEC-6 cells. Infect. Immun. 74:4114-4123.[Abstract/Free Full Text]
193 - Puthia, M. K., A. Vaithilingam, J. Lu, and K. S. Tan. 2005. Degradation of human secretory immunoglobulin A by Blastocystis. Parasitol. Res. 97:386-389.[CrossRef][Medline]
194 - Qadri, S. M., G. A. al-Okaili, and F. al-Dayel. 1989. Clinical significance of Blastocystis hominis. J. Clin. Microbiol. 27:2407-2409.[Abstract/Free Full Text]
195 - Reference deleted.
196 - Rao, K., U. Sekar, K. T. Iraivan, G. Abraham, and P. Soundararajan. 2003. Blastocystis hominis—an emerging cause of diarrhoea in renal transplant recipients. J. Assoc. Physicians India 51:719-721.[Medline]
197 - Rapeeporn, Y., N. Warunee, W. Nuttapong, S. Sompong, and K. Rachada. 2006. Infection of Blastocystis hominis in primary schoolchildren from Nakhon Pathom province, Thailand. Trop. Biomed. 23:117-122.[Medline]
198 - Rayan, H. Z., O. A. Ismail, and E. K. El Gayar. 2007. Prevalence and clinical features of Dientamoeba fragilis infections in patients suspected to have intestinal parasitic infection. J. Egypt. Soc. Parasitol. 37:599-608.[Medline]
199 - Reed, S. L., W. E. Keene, and J. H. McKerrow. 1989. Thiol proteinase expression and pathogenicity of Entamoeba histolytica. J. Clin. Microbiol. 27:2772-2777.[Abstract/Free Full Text]
200 - Requena, I., Y. Hernandez, M. Ramsay, C. Salazar, and R. Devera. 2003. Prevalence of Blastocystis hominis among food handlers from Caroni municipality, Bolivar State, Venezuela. Cad. Saude Publica 19:1721-1727. (In Spanish.)[Medline]
201 - Rivera, W. L. 2008. Phylogenetic analysis of Blastocystis isolates from animal and human hosts in the Philippines. Vet. Parasitol 156:178-182.[CrossRef][Medline]
202 - Rivera, W. L., and M. A. Tan. 2005. Molecular characterization of Blastocystis isolates in the Philippines by riboprinting. Parasitol. Res. 96:253-257.[CrossRef][Medline]
203 - Roger, A. J., and L. A. Hug. 2006. The origin and diversification of eukaryotes: problems with molecular phylogenetics and molecular clock estimation. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361:1039-1054.[Abstract/Free Full Text]
204 - Roger, A. J., O. Sandblom, W. F. Doolittle, and H. Philippe. 1999. An evaluation of elongation factor 1 alpha as a phylogenetic marker for eukaryotes. Mol. Biol. Evol. 16:218-233.[Abstract]
205 - Rossignol, J. F., S. M. Kabil, M. Said, H. Samir, and A. M. Younis. 2005. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. Clin. Gastroenterol. Hepatol. 3:987-991.[CrossRef][Medline]
206 - Russo, A. R., S. L. Stone, M. E. Taplin, H. J. Snapper, and G. V. Doern. 1988. Presumptive evidence for Blastocystis hominis as a cause of colitis. Arch. Intern. Med. 148:1064.[Abstract/Free Full Text]
207 - Sadaga, G. A., and H. H. Kassem. 2007. Prevalence of intestinal parasites among primary schoolchildren in Derna District, Libya. J. Egypt. Soc. Parasitol. 37:205-214.[Medline]
208 - Sadek, Y., A. F. el-Fakahany, A. H. Lashin, and F. A. el-Salam. 1997. Intestinal parasites among food-handlers in Qualyobia Governorate, with reference to the pathogenic parasite Blastocystis hominis. J. Egypt. Soc. Parasitol. 27:471-478.[Medline]
209 - Sajid, M., and J. H. McKerrow. 2002. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol. 120:1-21.[CrossRef][Medline]
210 - Saksirisampant, W., S. Nuchprayoon, V. Wiwanitkit, S. Yenthakam, and A. Ampavasiri. 2003. Intestinal parasitic infestations among children in an orphanage in Pathum Thani province. J. Med. Assoc. Thai. 86(Suppl. 2):S263-S270.[Medline]
211 - Saksirisampant, W., J. Prownebon, M. Kulkumthorn, S. Yenthakam, S. Janpla, and S. Nuchprayoon. 2006. Prevalence of intestinal parasitic infections among school children in the central region of Thailand. J. Med. Assoc. Thai. 89:1928-1933.[Medline]
211 - Salim, H. R., G. S. Kumar, S. Vellayan, J. W. Mak, A. K. Anuar, I. Init, G. D. Vennila, R. Saminathan, and K. Ramakrishnan. 1999. Blastocystis in animal handlers. Parasitol. Res. 85:1032-1033.[CrossRef][Medline]
212 - Schoepfer, A. M., M. Trummler, P. Seeholzer, D. H. Criblez, and F. Seibold. 2007. Accuracy of four fecal assays in the diagnosis of colitis. Dis. Colon Rectum 50:1697-1706.[CrossRef][Medline]
213 - Schoepfer, A. M., M. Trummler, P. Seeholzer, B. Seibold-Schmid, and F. Seibold. 2008. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm. Bowel Dis. 14:32-39.[CrossRef][Medline]
214 - Scicluna, S. M., B. Tawari, and C. G. Clark. 2006. DNA barcoding of Blastocystis. Protist 157:77-85.[Medline]
215 - Sheehan, D. J., B. G. Raucher, and J. C. McKitrick. 1986. Association of Blastocystis hominis with signs and symptoms of human disease. J. Clin. Microbiol. 24:548-550.[Abstract/Free Full Text]
216 - Shlim, D. R., C. W. Hoge, R. Rajah, J. G. Rabold, and P. Echeverria. 1995. Is Blastocystis hominis a cause of diarrhea in travelers? A prospective controlled study in Nepal. Clin. Infect. Dis. 21:97-101.[Medline]
217 - Silard, R. 1979. Contributions to Blastocystis hominis studies. Aspects of degenerescence. Arch. Roum. Pathol. Exp. Microbiol. 38:105-114.[Medline]
218 - Silberman, J. D., M. L. Sogin, D. D. Leipe, and C. G. Clark. 1996. Human parasite finds taxonomic home. Nature 380:398.[CrossRef][Medline]
219 - Singh, M., L. C. Ho, A. L. Yap, G. C. Ng, S. W. Tan, K. T. Moe, and E. H. Yap. 1996. Axenic culture of reptilian Blastocystis isolates in monophasic medium and speciation by karyotypic typing. Parasitol. Res. 82:165-169.[CrossRef][Medline]
220 - Singh, M., K. Suresh, L. C. Ho, G. C. Ng, and E. H. Yap. 1995. Elucidation of the life cycle of the intestinal protozoan Blastocystis hominis. Parasitol. Res. 81:446-450.[CrossRef][Medline]
221 - Sinniah, B., and B. Rajeswari. 1994. Blastocystis hominis infection, a cause of human diarrhea. Southeast Asian J. Trop. Med. Public Health 25:490-493.[Medline]
222 - Sio, S. W., M. K. Puthia, A. S. Lee, J. Lu, and K. S. Tan. 2006. Protease activity of Blastocystis hominis. Parasitol. Res. 99:126-130.[CrossRef][Medline]
223 - Snowden, K., K. Logan, C. Blozinski, J. Hoevers, and P. Holman. 2000. Restriction-fragment-length polymorphism analysis of small-subunit rRNA genes of Blastocystis isolates from animal hosts. Parasitol. Res. 86:62-66.[CrossRef][Medline]
224 - Sohail, M. R., and P. R. Fischer. 2005. Blastocystis hominis and travelers. Travel Med. Infect. Dis. 3:33-38.[CrossRef][Medline]
225 - Soriano, S. V., L. M. Barbieri, N. B. Pierangeli, A. L. Giayetto, A. M. Manacorda, E. Castronovo, B. C. Pezzani, M. Minvielle, and J. A. Basualdo. 2001. Intestinal parasites and the environment: frequency of intestinal parasites in children of Neuquen, Patagonia, Argentina. Rev. Latinoam. Microbiol. 43:96-101.[Medline]
226 - Staumont-Salle, D., D. Dombrowicz, M. Capron, and E. Delaporte. 2006. Eosinophils and urticaria. Clin. Rev. Allergy Immunol. 30:13-18.[CrossRef][Medline]
227 - Stensvold, C. R., M. C. Arendrup, C. Jespersgaard, K. Mølbak, and H. V. Nielsen. 2007. Detecting Blastocystis using parasitologic and DNA-based methods: a comparative study. Diagn. Microbiol. Infect. Dis. 59:303-307.[Medline]
228 - Stensvold, C. R., M. C. Arendrup, H. V. Nielsen, A. Bada, and S. Thorsen. 2008. Symptomatic infection with Blastocystis sp. subtype 8 successfully treated with trimethoprim-sulfamethoxazole. Ann. Trop. Med. Parasitol. 102:271-274.[CrossRef][Medline]
229 - Stensvold, C. R., G. K. Suresh, K. S. Tan, R. C. Thompson, R. J. Traub, E. Viscogliosi, H. Yoshikawa, and C. G. Clark. 2007. Terminology for Blastocystis subtypes—a consensus. Trends Parasitol. 23:93-96.[CrossRef][Medline]
230 - Stensvold, C. R., R. J. Traub, G. von Samson-Himmelstjerna, C. Jespersgaard, H. V. Nielsen, and R. C. Thompson. 2007. Blastocystis: subtyping isolates using pyrosequencing technology. Exp. Parasitol. 116:111-119.[CrossRef][Medline]
231 - Stensvold, R., A. Brillowska-Dabrowska, H. V. Nielsen, and M. C. Arendrup. 2006. Detection of Blastocystis hominis in unpreserved stool specimens by using polymerase chain reaction. J. Parasitol. 92:1081-1087.[CrossRef][Medline]
232 - Stenzel, D. J., and P. F. Boreham. 1994. Bacteria-like endosymbionts in Blastocystis sp. Int. J. Parasitol. 24:147-149.[CrossRef][Medline]
233 - Stenzel, D. J., and P. F. Boreham. 1996. Blastocystis hominis revisited. Clin. Microbiol. Rev. 9:563-584.[Abstract/Free Full Text]
234 - Stenzel, D. J., and P. F. Boreham. 1991. A cyst-like stage of Blastocystis hominis. Int. J. Parasitol. 21:613-615.[CrossRef][Medline]
235 - Stenzel, D. J., P. F. Boreham, and R. McDougall. 1991. Ultrastructure of Blastocystis hominis in human stool samples. Int. J. Parasitol. 21:807-812.[CrossRef][Medline]
236 - Stenzel, D. J., M. F. Cassidy, and P. F. Boreham. 1994. Morphology of Blastocystis sp. from domestic birds. Parasitol. Res. 80:131-137.[CrossRef][Medline]
237 - Stenzel, D. J., M. G. Lee, and P. F. Boreham. 1997. Morphological differences in Blastocystis cysts—an indication of different species? Parasitol. Res. 83:452-457.[CrossRef][Medline]
238 - Sun, T., S. Katz, B. Tanenbaum, and C. Schenone. 1989. Questionable clinical significance of Blastocystis hominis infection. Am. J. Gastroenterol. 84:1543-1547.[Medline]
239 - Suresh, K., S. Y. Chong, J. Howe, L. C. Ho, G. C. Ng, E. H. Yap, and M. Singh. 1995. Tubulovesicular elements in Blastocystis hominis from the caecum of experimentally-infected rats. Int. J. Parasitol. 25:123-126.[CrossRef][Medline]
240 - Suresh, K., J. Howe, S. Y. Chong, G. C. Ng, L. C. Ho, A. K. Loh, N. P. Ramachandran, E. H. Yap, and M. Singh. 1994. Ultrastructural changes during in vitro encystment of Blastocystis hominis. Parasitol. Res. 80:327-335.[CrossRef][Medline]
241 - Suresh, K., J. Howe, G. C. Ng, L. C. Ho, N. P. Ramachandran, A. K. Loh, E. H. Yap, and M. Singh. 1994. A multiple fission-like mode of asexual reproduction in Blastocystis hominis. Parasitol. Res. 80:523-527.[CrossRef][Medline]
242 - Suresh, K., J. W. Mak, L. S. Chuong, T. Ragunathan, and I. Init. 1997. Sac-like pouches in Blastocystis from the house lizard Cosymbotus platyurus. Parasitol. Res. 83:523-525.[CrossRef][Medline]
243 - Suresh, K., G. C. Ng, L. C. Ho, E. H. Yap, and M. Singh. 1994. Differentiation of the various stages of Blastocystis hominis by acridine orange staining. Int. J. Parasitol. 24:605-606.[CrossRef][Medline]
244 - Suresh, K., G. C. Ng, N. P. Ramachandran, L. C. Ho, E. H. Yap, and M. Singh. 1993. In vitro encystment and experimental infections of Blastocystis hominis. Parasitol. Res. 79:456-460.[CrossRef][Medline]
245 - Suresh, K., and H. Smith. 2004. Comparison of methods for detecting Blastocystis hominis. Eur. J. Clin. Microbiol. Infect. Dis. 23:509-511.[CrossRef][Medline]
246 - Suresh, K., H. V. Smith, and T. C. Tan. 2005. Viable Blastocystis cysts in Scottish and Malaysian sewage samples. Appl. Environ. Microbiol. 71:5619-5620.[Abstract/Free Full Text]
247 - Svenungsson, B., A. Lagergren, E. Ekwall, B. Evengård, K. O. Hedlund, A. Kärnell, S. Löfdahl, L. Svensson, and A. Weintraub. 2000. Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases. Clin. Infect. Dis. 30:770-778.[CrossRef][Medline]
248 - Taamasri, P., M. Mungthin, R. Rangsin, B. Tongupprakarn, W. Areekul, and S. Leelayoova. 2000. Transmission of intestinal blastocystosis related to the quality of drinking water. Southeast Asian J. Trop. Med. Public Health 31:112-117.[Medline]
249 - Tan, H. K., and C. H. Zierdt. 1973. Ultrastructure of Blastocystis hominis. Z. Parasitenkd. 42:315-324.[CrossRef][Medline]
250 - Tan, K. S. 2004. Blastocystis in humans and animals: new insights using modern methodologies. Vet. Parasitol. 126:121-144.[CrossRef][Medline]
251 - Tan, K. S. 2008. Blastocystis spp. In N. A. Khan (ed.), Emerging protozoan pathogens. Taylor and Francis, Oxford, United Kingdom.
252 - Tan, K. S., J. Howe, E. H. Yap, and M. Singh. 2001. Do Blastocystis hominis colony forms undergo programmed cell death? Parasitol. Res. 87:362-367.[CrossRef][Medline]
253 - Tan, K. S., M. Ibrahim, G. C. Ng, A. M. Nasirudeen, L. C. Ho, E. H. Yap, and M. Singh. 2001. Exposure of Blastocystis species to a cytotoxic monoclonal antibody. Parasitol. Res. 87:534-538.[CrossRef][Medline]
254 - Tan, K. S., and A. M. Nasirudeen. 2005. Protozoan programmed cell death—insights from Blastocystis deathstyles. Trends Parasitol. 21:547-550.[CrossRef][Medline]
255 - Tan, K. S., G. C. Ng, E. Quek, J. Howe, N. P. Ramachandran, E. H. Yap, and M. Singh. 2000. Blastocystis hominis: a simplified, high-efficiency method for clonal growth on solid agar. Exp. Parasitol. 96:9-15.[CrossRef][Medline]
256 - Tan, K. S., M. Singh, and E. H. Yap. 2002. Recent advances in Blastocystis hominis research: hot spots in terra incognita. Int. J. Parasitol. 32:789-804.[CrossRef][Medline]
257 - Tan, K. S., and D. J. Stenzel. 2003. Multiple reproductive processes in Blastocystis: proceed with caution. Trends Parasitol. 19:290-291, 291-292.[CrossRef][Medline]
258 - Tan, S. W., L. C. Ho, K. T. Moe, X. Q. Chen, G. C. Ng, E. H. Yap, and M. Singh. 1996. Production and characterization of murine monoclonal antibodies to Blastocystis hominis. Int. J. Parasitol. 26:375-381.[CrossRef][Medline]
259 - Tan, S. W., M. Singh, L. C. Ho, J. Howe, K. T. Moe, X. Q. Chen, G. C. Ng, and E. H. Yap. 1997. Survival of Blastocystis hominis clones after exposure to a cytotoxic monoclonal antibody. Int. J. Parasitol. 27:947-954.[CrossRef][Medline]
260 - Tan, S. W., M. Singh, K. T. Thong, L. C. Ho, K. T. Moe, X. Q. Chen, G. C. Ng, and E. H. Yap. 1996. Clonal growth of Blastocystis hominis in soft agar with sodium thioglycollate. Parasitol. Res. 82:737-739.[CrossRef][Medline]
261 - Tan, S. W., M. Singh, E. H. Yap, L. C. Ho, K. T. Moe, J. Howe, and G. C. Ng. 1996. Colony formation of Blastocystis hominis in soft agar. Parasitol. Res. 82:375-377.[CrossRef][Medline]
262 - Tan, T. C., and K. G. Suresh. 2006. Amoeboid form of Blastocystis hominis—a detailed ultrastructural insight. Parasitol. Res. 99:737-742.[CrossRef][Medline]
263 - Tan, T. C., and K. G. Suresh. 2007. Evidence of plasmotomy in Blastocystis hominis. Parasitol. Res. 101:1521-1525.[CrossRef][Medline]
264 - Tan, T. C., and K. G. Suresh. 2006. Predominance of amoeboid forms of Blastocystis hominis in isolates from symptomatic patients. Parasitol. Res. 98:189-193.[CrossRef][Medline]
265 - Tan, T. C., K. G. Suresh, K. L. Thong, and H. V. Smith. 2006. PCR fingerprinting of Blastocystis isolated from symptomatic and asymptomatic human hosts. Parasitol. Res. 99:459-465.[CrossRef][Medline]
266 - Tanizaki, A., H. Yoshikawa, S. Iwatani, and I. Kimata. 2005. Infectivity of Blastocystis isolates from chickens, quails and geese in chickens. Parasitol. Res. 96:57-61.[CrossRef][Medline]
267 - Tasova, Y., B. Sahin, S. Koltas, and S. Paydas. 2000. Clinical significance and frequency of Blastocystis hominis in Turkish patients with hematological malignancy. Acta Med. Okayama 54:133-136.[Medline]
268 - Tato, C. M., and C. A. Hunter. 2002. Host-pathogen interactions: subversion and utilization of the NF-
B pathway during infection. Infect. Immun. 70:3311-3317.[Free Full Text] 269 - Teow, W. L., G. C. Ng, P. P. Chan, Y. C. Chan, E. H. Yap, V. Zaman, and M. Singh. 1992. A survey of Blastocystis in reptiles. Parasitol. Res. 78:453-455.[CrossRef][Medline]
270 - Termmathurapoj, S., S. Leelayoova, P. Aimpun, U. Thathaisong, T. Nimmanon, P. Taamasri, and M. Mungthin. 2004. The usefulness of short-term in vitro cultivation for the detection and molecular study of Blastocystis hominis in stool specimens. Parasitol. Res. 93:445-447.[Medline]
271 - Thathaisong, U., J. Worapong, M. Mungthin, P. Tan-Ariya, K. Viputtigul, A. Sudatis, A. Noonai, and S. Leelayoova. 2003. Blastocystis isolates from a pig and a horse are closely related to Blastocystis hominis. J. Clin. Microbiol. 41:967-975.[Abstract/Free Full Text]
272 - Tiwary, B. K., and M. C. Goel. 1984. Suppression of IgA synthesis in chickens. Vet. Immunol. Immunopathol. 7:305-313.[CrossRef][Medline]
273 - Torres, P., J. C. Miranda, L. Flores, J. Riquelme, R. Franjola, J. Pérez, S. Auad, C. Hermosilla, and S. Riquelme. 1992. Blastocystosis and other intestinal protozoan infections in human riverside communities of the Valdivia River basin, Chile. Rev. Inst. Med. Trop. Sao Paulo 34:557-564. (In Portugese.)[Medline]
274 - Tungtrongchitr, A., S. Manatsathit, C. Kositchaiwat, J. Ongrotchanakun, N. Munkong, P. Chinabutr, S. Leelakusolvong, and W. Chaicumpa. 2004. Blastocystis hominis infection in irritable bowel syndrome patients. Southeast Asian J. Trop. Med. Public Health 35:705-710.[Medline]
275 - Udkow, M. P., and E. K. Markell. 1993. Blastocystis hominis: prevalence in asymptomatic versus symptomatic hosts. J. Infect. Dis. 168:242-244.[Medline]
276 - Upcroft, J. A., L. A. Dunn, L. S. Dommett, A. Healey, P. Upcroft, and P. F. Boreham. 1989. Chromosomes of Blastocystis hominis. Int. J. Parasitol. 19:879-883.[CrossRef][Medline]
277 - Valido, E. M., and W. L. Rivera. 2007. Colony growth of Philippine isolates of Blastocystis hominis in simplified, soft agar medium. Parasitol. Res. 101:213-217.[CrossRef][Medline]
278 - Valsecchi, R., P. Leghissa, and V. Greco. 2004. Cutaneous lesions in Blastocystis hominis infection. Acta Derm. Venereol. 84:322-323.[CrossRef][Medline]
279 - van der Heijden, H. M., and W. J. Landman. 2008. In vitro effect of herbal products against Histomonas meleagridis. Vet. Parasitol. 154:1-7.[CrossRef][Medline]
280 - Vannatta, J. B., D. Adamson, and K. Mullican. 1985. Blastocystis hominis infection presenting as recurrent diarrhea. Ann. Intern. Med. 102:495-496.[Abstract/Free Full Text]
281 - Vennila, G. D., G. S. Kumar, A. K. Anuar, S. Rajah, R. Saminathan, S. Sivanandan, and K. Ramakrishnan. 1999. Irregular shedding of Blastocystis hominis. Parasitol. Res. 85:162-164.[CrossRef][Medline]
282 - Villar, J., J. A. Carbajal, M. D. Lanuza, C. Muñoz, and R. Borrás. 1998. In vitro encystation of Blastocystis hominis: a kinetics and cytochemistry study. Parasitol. Res. 84:54-58.[CrossRef][Medline]
283 - Visser, L. G., J. J. Verweij, M. Van Esbroeck, W. M. Edeling, J. Clerinx, and A. M. Polderman. 2006. Diagnostic methods for differentiation of Entamoeba histolytica and Entamoeba dispar in carriers: performance and clinical implications in a non-endemic setting. Int. J. Med. Microbiol. 296:397-403.[CrossRef][Medline]
284 - Waghorn, D. J., and P. Hancock. 1991. Clinical significance of Blastocystis hominis. Lancet 337:609.[Medline]
285 - Waikagul, J., S. Krudsood, P. Radomyos, B. Radomyos, K. Chalemrut, P. Jonsuksuntigul, S. Kojima, S. Looareesuwan, and W. Thaineau. 2002. A cross-sectional study of intestinal parasitic infections among schoolchildren in Nan Province, Northern Thailand. Southeast Asian J. Trop. Med. Public Health 33:218-223.[Medline]
286 - Walderich, B., S. Bernauer, M. Renner, J. Knobloch, and G. D. Burchard. 1998. Cytopathic effects of Blastocystis hominis on Chinese hamster ovary (CHO) and adeno carcinoma HT29 cell cultures. Trop. Med. Int. Health 3:385-390.[CrossRef][Medline]
287 - Wang, L. C. 2004. Changing patterns in intestinal parasitic infections among Southeast Asian laborers in Taiwan. Parasitol. Res. 92:18-21.[CrossRef][Medline]
288 - Wilson, K. W., D. Winget, and S. Wilks. 1990. Blastocystis hominis infection: signs and symptoms in patients at Wilford Hall Medical Center. Mil. Med. 155:394-396.[Medline]
289 - Windsor, J. J., L. Macfarlane, G. Hughes-Thapa, S. K. Jones, and T. M. Whiteside. 2002. Incidence of Blastocystis hominis in faecal samples submitted for routine microbiological analysis. Br. J. Biomed. Sci. 59:154-157.[Medline]
290 - Windsor, J. J., D. J. Stenzel, and L. Macfarlane. 2003. Multiple reproductive processes in Blastocystis hominis. Trends Parasitol. 19:289-290, 291-292.[CrossRef][Medline]
291 - Wong, K. H., G. C. Ng, R. T. Lin, H. Yoshikawa, M. B. Taylor, and K. S. Tan. 2008. Predominance of subtype 3 among Blastocystis isolates from a major hospital in Singapore. Parasitol. Res. 102:663-670.[CrossRef][Medline]
292 - Yakoob, J., W. Jafri, N. Jafri, M. Islam, and M. Asim Beg. 2004. In vitro susceptibility of Blastocystis hominis isolated from patients with irritable bowel syndrome. Br. J. Biomed. Sci. 61:75-77.[Medline]
293 - Yakoob, J., W. Jafri, N. Jafri, R. Khan, M. Islam, M. A. Beg, and V. Zaman. 2004. Irritable bowel syndrome: in search of an etiology: role of Blastocystis hominis. Am. J. Trop. Med. Hyg. 70:383-385.[Abstract/Free Full Text]
294 - Yan, Y., S. Su, R. Lai, H. Liao, J. Ye, X. Li, X. Luo, and G. Chen. 2006. Genetic variability of Blastocystis hominis isolates in China. Parasitol. Res. 99:597-601.[CrossRef][Medline]
295 - Yan, Y., S. Su, J. Ye, X. Lai, R. Lai, H. Liao, G. Chen, R. Zhang, Z. Hou, and X. Luo. 2007. Blastocystis sp. subtype 5: a possibly zoonotic genotype. Parasitol. Res. 101:1527-1532.[CrossRef][Medline]
296 - Yoshikawa, H., N. Abe, M. Iwasawa, S. Kitano, I. Nagano, Z. Wu, and Y. Takahashi. 2000. Genomic analysis of Blastocystis hominis strains isolated from two long-term health care facilities. J. Clin. Microbiol. 38:1324-1330.[Abstract/Free Full Text]
297 - Yoshikawa, H., N. Abe, and Z. Wu. 2004. PCR-based identification of zoonotic isolates of Blastocystis from mammals and birds. Microbiology 150:1147-1151.[Abstract/Free Full Text]
298 - Yoshikawa, H., I. Katagiri, X. H. Li, M. BeckerHapak, and D. C. Graves. 1995. Antigenic differences between Blastocystis hominis and Blastocystis sp. revealed by polyclonal and monoclonal antibodies. J. Protozool. Res. 5:118-128.
299 - Yoshikawa, H., N. Kuwayama, and Y. Enose. 1995. Histochemical detection of carbohydrates of Blastocystis hominis. J. Eukaryot. Microbiol. 42:70-74.[Medline]
300 - Yoshikawa, H., K. Morimoto, Z. Wu, M. Singh, and T. Hashimoto. 2004. Problems in speciation in the genus Blastocystis. Trends Parasitol. 20:251-255.[CrossRef][Medline]
301 - Yoshikawa, H., I. Nagano, Z. Wu, E. H. Yap, M. Singh, and Y. Takahashi. 1998. Genomic polymorphism among Blastocystis hominis strains and development of subtype-specific diagnostic primers. Mol. Cell. Probes 12:153-159.[CrossRef][Medline]
302 - Yoshikawa, H., J. Satoh, and Y. Enose. 1995. Light and electron microscopic localization of lipids in Blastocystis hominis. J. Electron Microsc. (Tokyo) 44:100-103.[Abstract/Free Full Text]
303 - Yoshikawa, H., Z. Wu, J. Howe, T. Hashimoto, N. Geok-Choo, and K. S. Tan. 2007. Ultrastructural and phylogenetic studies on Blastocystis isolates from cockroaches. J. Eukaryot. Microbiol. 54:33-37.[CrossRef][Medline]
304 - Yoshikawa, H., Z. Wu, I. Kimata, M. Iseki, I. K. Ali, M. B. Hossain, V. Zaman, R. Haque, and Y. Takahashi. 2004. Polymerase chain reaction-based genotype classification among human Blastocystis hominis populations isolated from different countries. Parasitol. Res. 92:22-29.[CrossRef][Medline]
305 - Yoshikawa, H., Z. Wu, I. Nagano, and Y. Takahashi. 2003. Molecular comparative studies among Blastocystis isolates obtained from humans and animals. J. Parasitol. 89:585-594.[CrossRef][Medline]
306 - Yoshikawa, H., K. Yoshida, A. Nakajima, K. Yamanari, S. Iwatani, and I. Kimata. 2004. Fecal-oral transmission of the cyst form of Blastocystis hominis in rats. Parasitol. Res. 94:391-396.[CrossRef][Medline]
307 - Zaki, M., A. S. Daoud, R. N. Pugh, F. al-Ali, G. al-Mutairi, and Q. al-Saleh. 1991. Clinical report of Blastocystis hominis infection in children. J. Trop. Med. Hyg. 94:118-122.[Medline]
308 - Zali, M. R., A. J. Mehr, M. Rezaian, A. R. Meamar, S. Vaziri, and M. Mohraz. 2004. Prevalence of intestinal parasitic pathogens among HIV-positive individuals in Iran. Jpn. J. Infect. Dis. 57:268-270.[Medline]
309 - Zaman, V. 1996. The diagnosis of Blastocystis hominis cysts in human faeces. J. Infect. 33:15-16.[CrossRef][Medline]
310 - Zaman, V. 1998. The differential identification of Blastocystis hominis cysts. Ann. Trop. Med. Parasitol. 92:233-235.[CrossRef][Medline]
311 - Zaman, V., J. Howe, and M. Ng. 1997. Observations on the surface coat of Blastocystis hominis. Parasitol. Res. 83:731-733.[CrossRef][Medline]
312 - Zaman, V., J. Howe, and M. Ng. 1995. Ultrastructure of Blastocystis hominis cysts. Parasitol. Res. 81:465-469.[CrossRef][Medline]
313 - Zaman, V., J. Howe, and M. Ng. 1997. Variation in the cyst morphology of Blastocystis hominis. Parasitol. Res. 83:306-308.[CrossRef][Medline]
314 - Zaman, V., J. Howe, M. Ng, and T. K. Goh. 1999. Scanning electron microscopy of the surface coat of Blastocystis hominis. Parasitol. Res. 85:974-976.[CrossRef][Medline]
315 - Zaman, V., and K. Z. Khan. 1994. A concentration technique for obtaining viable cysts of Blastocystis hominis from faeces. J. Pak. Med. Assoc. 44:220-221.[Medline]
316 - Zaman, V., and M. Zaki. 1996. Resistance of Blastocystis hominis cysts to metronidazole. Trop. Med. Int. Health 1:677-678.[Medline]
317 - Zaman, V., M. Zaki, M. Manzoor, J. Howe, and M. Ng. 1999. Postcystic development of Blastocystis hominis. Parasitol. Res. 85:437-440.[CrossRef][Medline]
318 - Zhang, X., J. Y. Qiao, X. J. Zhou, F. R. Yao, and Z. C. Wei. 2007. Morphology and reproductive mode of Blastocystis hominis in diarrhea and in vitro. Parasitol. Res. 101:43-51.[CrossRef][Medline]
319 - Zierdt, C. H. 1991. Blastocystis hominis—past and future. Clin. Microbiol. Rev. 4:61-79.[Abstract/Free Full Text]
320 - Zierdt, C. H. 1988. Blastocystis hominis, a long-misunderstood intestinal parasite. Parasitol. Today 4:15-17.[CrossRef][Medline]
321 - Zierdt, C. H. 1973. Studies of Blastocystis hominis. J. Protozool. 20:114-121.[Medline]
322 - Zierdt, C. H., C. T. Donnolley, J. Muller, and G. Constantopoulos. 1988. Biochemical and ultrastructural study of Blastocystis hominis. J. Clin. Microbiol. 26:965-970.[Abstract/Free Full Text]
323 - Zierdt, C. H., and B. Nagy. 1993. Antibody response to Blastocystis hominis infections. Ann. Intern. Med. 118:985-986.[Free Full Text]
324 - Zierdt, C. H., and J. C. Swan. 1981. Generation time and growth rate of the human intestinal parasite Blastocystis hominis. J. Protozool. 28:483-485.[Medline]
325 - Zierdt, C. H., J. C. Swan, and J. Hosseini. 1983. In vitro response of Blastocystis hominis to antiprotozoal drugs. J. Protozool. 30:332-334.[Medline]
326 - Zierdt, C. H., and H. K. Tan. 1976. Ultrastructure and light microscope appearance of Blastocystis hominis in a patient with enteric disease. Z. Parasitenkd. 50:277-283.[CrossRef][Medline]
327 - Zierdt, C. H., and R. L. Williams. 1974. Blastocystis hominis: axenic cultivation. Exp. Parasitol. 36:233-243.[CrossRef][Medline]
328 - Zierdt, C. H., W. S. Zierdt, and B. Nagy. 1995. Enzyme-linked immunosorbent assay for detection of serum antibody to Blastocystis hominis in symptomatic infections. J. Parasitol. 81:127-129.[CrossRef][Medline]
329 - Zuckerman, M. J., H. Ho, L. Hooper, B. Anderson, and S. M. Polly. 1990. Frequency of recovery of Blastocystis hominis in clinical practice. J. Clin. Gastroenterol. 12:525-532.[Medline]
330 - Zuckerman, M. J., M. T. Watts, H. Ho, and F. V. Meriano. 1994. Blastocystis hominis infection and intestinal injury. Am. J. Med. Sci. 308:96-101.[Medline]
Clinical Microbiology Reviews, October 2008, p. 639-665, Vol. 21, No. 4
0893-8512/08/$08.00+0 doi:10.1128/CMR.00022-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Vassalos, C. M., Spanakos, G., Vassalou, E., Papadopoulou, C., Vakalis, N.
(2010). Differences in Clinical Significance and Morphologic Features of Blastocystis sp Subtype 3. Am J Clin Pathol
133: 251-258
[Abstract]
[Full Text]
-
Wu, B., Yin, J., Texier, C., Roussel, M., Tan, K. S.-W.
(2010). Blastocystis Legumain Is Localized on the Cell Surface, and Specific Inhibition of Its Activity Implicates a Pro-survival Role for the Enzyme. J. Biol. Chem.
285: 1790-1798
[Abstract]
[Full Text]
-
Boeke, C. E., Mora-Plazas, M., Forero, Y., Villamor, E.
(2010). Intestinal Protozoan Infections in Relation to Nutritional Status and Gastrointestinal Morbidity in Colombian School Children. J Trop Pediatr
0: fmp136v1-fmp136
[Abstract]
[Full Text]